annual report p e n n n v n p r n e r cancer modern care help advanced analytic enable roche expand colla b effective treatment create wealth new data insight oration combine available previously innovative opportunity strength unique tool therapy allow woman entire product lifecycle rd partner elevate personalise cover picture carry value chain ultimately improve healthcare new level life cover outcome patient patientskeith terry genentech usa emotional hire medical doctor talent scout genentech family friendsand dwell south san francisco work closely negative teach stay moment product development neuroscience team ironically time big win hire senior medical experienced relapse feel fatigued director ocrevus medication currently effort breathe difficult imagine use treat multiple sclerosis ms level fatigue experience emotional hire illness increase capacity empathy ill diagnose multiple sclerosis year ago age experience extreme overall positive fatigue loss motor function hand meet amazing people ms time numbness torso experience active member arm believe ms year actually ms society lead support group individual diagnose prior ignore ms year participate fatigue thought happen local ms walk community try get old get vitamin exercise day capacity power feel fatigued major help good diet event occur ignore important challenge motor function hand definitely decrease happen lead hire initiative shortterm memory affect bank write white board keep drop pen feel weak left arm ms sayget involved hand thought heart attack great thing go ms community end emergency room heart ignore symptom include depression condition send home keep feel bad common symptom ignore worse visit different emergency medical depression relate ms good centre mri show lesion spinal day bad day illness cord brain multiple sclerosis start take ocrevus year half ago day good high level diagnosis focus important energy thankful thingsdeveloping enhance relationshipsinnovation dna work discipline geography drive scientific discovery redefine possible improve patient live work understanding disease world leader vitro diagnostic differ molecular level develop business track record allow build last new test medicine prevent diagnose meaningful partnership world treat disease bring patient research academia public healthcare institution need combined strength diagnostic pharmaceutical personalise founding family continue hold majority healthcare strategy aim fit right treatment voting stake company stability allow right patient tradition sustainable thinking learn setback focus last value patient world large biotech company develop society remain dedicated high breakthrough medicine improve standard standard quality safety integrity legacy care oncology immunology infectious base respect individual disease ophthalmology neuroscience community world live employee worldwide north america europe employee employee genentech south san francisco basel kaiseraugst rotkreuz switzerland roche diagnostic indianapoli mannheim penzberg germany asia employees chugai tokyo japan shanghai suzhou china latin america employees africa australianew zealand employee employee research development site manufacture site pharmaceutical pharmaceutical diagnostic worldwide diagnostic worldwide roche group headquarters manufacturing site pharmaceutical diagnostic large site base number employee sale site pharmaceutical diagnostic research development site pharmaceutical diagnostic number employee express fulltime equivalentshighlight support continued growth progress alzheimer diagnosis chf billion salesocrevus form fda breakthrough device designation elecsy assay ms successful new product launch roche support early improve diagnosis alzheimer disease read read treat rare blood disorder improve access healthcare hemlibra indicate haemophilia patient roche take lead role scaleup city cancer challenge change global landscape cancer care read read fight influenza infection contribute sustainability xofluzafirst singledose oral medicine treat influenza roche rank sustainable healthcare company approve dow jones sustainability indices tenth successive year read read key figure chf million chf million group sale rd core investment chf million roche medicine core operate profit model list essential medicine chf million patient dividend treat roche medicine growth rate report constant exchange rate cer average content overview strategy chairman shareholder letter interview ceo roche group business performance group performance diagnostic performance pharmaceutical performance science innovation datum insight well inform decision harness frontline scientific technology access healthcare digital platform support patient continue fight hivaid people increase agility drive manage change nurture attract talent environment decrease energy consumption reduce greenhouse gas emission community engagement path strong society unlock potential grow talent integrity business ensure operational resilience partnership last future corporate governance board director corporate executive committee remuneration report principle remuneration component report approach roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance report scope boundary emerge sustainability risk opportunitie financial nonfinancial reporting consist provide risk management web annual report finance report online report contain annual financial statement consolidated group risk report cover consolidated financial statement nonfinancial material risk discuss annually performance indicator cover region corporate executive committee review division january december audit committee board director financial reporting scope define outlined board director effectiveness group risk finance report significant management process regularly monitor group change scope compare risk advisory team overall process review externally appropriate risk management reporting accordance late embed level group pharmaceutical gri guideline diagnostic division global function conduct follow gri g guideline global formal risk assessment process year reporting initiative gri develop risk plan material risk guideline disclose critical impact activity environment society economy group risk advisory facilitate risk discussion report period transition support business specialist area newly introduce gri standard base security compliance sustainability key concept disclosure gri g training session platform establish guideline report accordance standard help employee manage monitor mitigate risk core level requirement appropriately core level number indicator read corporate governance risk management risk management policy set roche approach external assurance identify analyse manage report current annual report include independent internal external risk opportunity assurance report nonfinancial reporting identify business sustainability risk opportunity prepare pricewaterhousecoopers ag annual basis integrate exist group risk management process information independent assurance report report approach roche material topic tier fundamental driver ability deliver core purpose long term rd pipeline strategy personalise healthcare employee engagement talent retention growth strategy emerge develop market product portfolio strategy patent policy leadership commitment materiality tier major influence factor business accordance gri standard conduct success short medium term materiality analysis corporate level pricing gather input feedback disease awareness treatment education internal external source conference compliance conduct regular interview oneonone drug efficacy safety counterfeit discussion key stakeholder result supply chain management regularly vet ongoing stakeholder biosimilar safety research key market stakeholder group sustainable healthcare enable include topic stakeholder group consider important business tier additional material topic healthcare sector patient organisation executive remuneration physicians laboratory staff employee medium compensationbenefit investor payer regulator government organisational effectiveness environmental responsibility material topic screen community engagement priority deem key roche tiersfirstly patient organisation support fundamental driver ability deliver datum transparency clinical trial core purpose long term secondly additional occupational accident annually review major influence factor business success short medium term finally material topic provide level priority address material topic materiality rochecommateriality tier material topic reflect business priority report content key performance indicator highlight begin chapter rochecomperformance aspect boundary accord gri build concrete action relate topic online roche annual report operational activity measure performance arrochecom define indicator roche annual report pdf currently conduct second global rochecomarepdf materiality assessment result assessment publish website roche finance report pdf inform strategy move forward rochecomfbepdf content annual report risk management strategy rochecomriskmanagement commitment un sdgs global healthcare company commit support number united nations sustainable development goal sdgs line business strategy particular contribution un sdgs sdg aim ensure healthy live rochecomunsdgssustainable development goal roche history year strong commitment sustainability support sdg innovate patient million patient treat roche medicine billion test conduct roche diagnostic products roche medicine model list essential medicine trustworthy partner new partnership diagnostic new partnership pharmaceutical approximately businesscritical supplier riskassesse protect environment decrease water consumption decrease energy consumption improvement ecobalance deliver continue growth group sale core operate profit sustainability leader accord dow jones sustainability index provide great workplace employee engagement rate key leadership position hold woman key leader diverse work experience world health organization growth rate report constant exchange rate cer average measure global employee opinion survey focus people fitting treatment patient make mark distinctiveness decisionmake excellence science accountable transparent delivery structure value stakeholder build innovation itour strategy roche strategy focus find new medicine diagnostic help patient live long well life evolve practice medicine guide purpose molecular biology seamless integration patient need pharmaceutical diagnostic capability company year history diversity approach maximise innovation advance field medicine bring novel longterm orientation treatment diagnostic patient patient remain core reason delivery create value stakeholder come work day partner choice bring significant medical benefit patient doctor payer offer great place work employee deliver sustainable positive contribution society create topquartile total shareholder return focus fitting treatment patient investor provide right therapy group people respond well right time inhouse combination pharmaceutical diagnostic uniquely position deliver personalise healthcare develop internal capability ultimately take people integrity courage build strategic partnership ready passion difference patient stage personalise healthcare combine insight people proud roche multiple data source sophisticated analytic embrace diversity culture people drive effective efficient research allow group inclusive encourage well therapeutic decision patient access richness idea approach bring product critical strategy detail access plan embed decisionmake principle process business local level emphasise transparent dialogue clear accountability encourage high degree empowerment continue concentrate energy entirely prescription medicine vitro diagnostic structure build innovation autonomous diversify sector like generics research development centre alliance biosimilar overthecounter medicine external partner foster diversity scientific approach agility global geographical scale pursuit excellence science reach enable attract talent big distinctiveness rest key element global science cluster bring diagnostic exceptionally broad deep understanding medicine quickly people need personalised healthcare take leveldigitalisation trigger business transformation digitalisation refer use digital technology increasingly see potentially rich modify exist business model life science underutilise source generate benefit way company healthcare provider patient addition insight derive realworld consumer use digital technology believe datum offer prospect take personalise harbour significant potential streamlining healthcare level diagnosis treatment process help achieve superior treatment highly tailor term effectiveness outcome safety individual unique condition b link clinical trial datum realworld datum underlie view number recent dramatic advance biological medical development quality health datum knowledge expect provide lead available electronic form new digital capability target research efficient development process common practice include record health datum digitally example low way evolution require partnership cost mobile device transform exist traditional player healthcare provider record note image format suitable payer life science expert device manufacturer machine learn curate datum efficiently nontraditional entrant retailer depth datum enhance novel datum type telecommunication technology company characteristic example genetic profile entrepreneur venture capital investors consistent datum long time period second tool advance analysis large datum volume embed digitalisation organisation emerge advance compute power datum roche pharmaceutical digitalisation tran handle sophisticated analysis technique form way medicine develop test adopt healthcare deliver patient leverage rapidly increase volume healthrelate datum diagnostic test result explosive growth result critical development highquality datum analyse sophisticated medicine roche diagnostic interpret particularly datum accessible datadriven process allow optimise workflow routine clinical practice capture electronic laboratory medical decisionmake medical record refer realworld datum improve laboratory efficiency treatment efficacypersonalise healthcare roche datum management pharmaceutical diagnostic personalise healthcarethe level ms progressive disease start pursue level personalise healthcare ability characterise prognose individual add dimension roche expertise disease course realworld limited pharmaceutical diagnostic datum management introduction smartphone wearable roche rapidly expand exist capability technology carry ability continuously deploy internally externally track health example floodlight use smartphone sensorbase measure large data set allow well insight detect subtle change cognition motor partnership foundation medicine function develop novel measure disease inc usa specialise genetic profiling cancer progression aim empower people flatiron health curate electronic medical ms information disease record build meaningful healthcare professional tool recognise datum scale combine dataset progression fundamentally improve deep understanding cancer diagnostic understand ms individualise patient care treatment look specific pattern range determine prevalence cancer biomarker support manage increasingly complex datum identify potential druggable target rapidly increase wealth complexity insight increasingly allow answer question datum represent formidable challenge healthcare answer example professional roche navify decision support small patient population provide effective portfolio fully integrate clinical workflow intervention option cancer patient solution clinical decision support app help multidisciplinary care team navigate maze understanding disease progression ms medical information analytic transform personalise healthcare aim improve outcome large amount datum actionable insight patient multiple sclerosis ms mean detect disease progression early develop tool accelerate drug development kpmg digitalisation life science ey healthcarethe crosscurrents convergence deliver participatory health year strong growth dear shareholder view increase competition biosimilar particularly encourage note sale digitalisation permeating significant growth drive innovative new area live healthcare sector medicine ocrevus perjeta breast cancer exception severin schwan explain page tecentriq cancer immunotherapy alecensa lung digitalisation present tremendous opportunity cancer hemlibra haemophilia researchbase diagnostic pharmaceutical immuno diagnostic business company roche intend leverage broadly support opportunity provide well diagnostic decisionmake support doctor roche good product pipeline develop muchneede treatment fast industry invest chf billion target way example effort include development leader oncology finalise transaction foundation medicine grow number neuroscience project acquisition flatiron health united states immunology perform help improve ongoing effort year food drug administration personalise healthcare grant breakthrough therapy designation few roche active ingredient late medical innovation particular achievement proud reason optimistic outlook roche future ocrevus approve multiple sclerosis ms strength innovation reflect successful product launch roche financial result roche increase sale history effective relapse form ms chf billion ifrs net income rise case patient condition steadily worsen chf billion owe positive business outset ocrevus medicine performance propose dividend approve primary progressive form ms swiss franc share nonvoting equitychairman shareholder letter roche security annual general meeting company university recent march subject approval example influenza medicine xofluza initial nd consecutive dividend increase research compound carry japanese pharmaceutical company shionogi delight nomination professor subsequently develop roche partnership dr hans clevers professor molecular genetics shionogi xofluza receive fasttrack approval university medical center utrecht netherlands united states october election board director professor influenza treatment novel mechanism clever outstanding scientist great expertise action year experience medical research focus personalise healthcare aim gratifying sustainability sustain growth trajectory mindset embed level company confident pursue strategy systematic roche recognise group leader innovation base medical scientific progress sustainability pharmaceutical sustainable solution partnership roche biotechnology life science industry index position future dow jones sustainability indices tenth consecutive year commitment continue thank work operating business responsibly holistically behalf patient world thank longterm perspective employee tireless effort achievement important contribution society development offer shareholder heartfelt thank medicine diagnostic significantly trust place improve people life year billion test conduct roche analyser million patient worldwide benefit medicine roche company consolidate complement research development expertise work external partner dr christoph franz worldwide partnership chairman board director growth rate report constant exchange rate cer average board director roche board directors paul bulcke b e prof sir john bell b e bernard poussot c e anita hauser e dr andreas oeri representative shareholder group pool voting right e andr hoffmann vicechairman representative shareholder group pool voting right c e dr severin schwan f dr christoph franz chairman c e dr claudia suessmuth dyckerhoff b e julie brown b e prof dr richard p lifton c e peter r voser c e corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche board director december midst roche apprenticesboard director roche data protection dna roche ceo severin schwan talk completely new opportunity open digitalisation importance trust handle patient datum digitalisation mean roche new business technologiescombine expertise division compile clinical trial datum medical sciencehave potential fundamentally basis obtain approval new medicine improve accelerate way research s new long evaluate datum develop sell medicine diagnostic system clinical trial data clinical practice continue stand diagnostic reason data medicine market increase number increasingly compile record electronically digital solution alongside tangible product pharmaceutical diagnostic division talk flatiron fmi experience impact business model s right acquire flatiron fmi different way pharmaceutical assess datum take quantum leap forward term access tointerview ceo roche group roche datum oncology company pursue available achieve basically want work objective independently addition anonymise datum instead access sensitive enter large number partnership personal datum thank powerful anonymisation company public institution process data utilisation contravene datum pharmaceutical business model change protection connection like fundamentally focus development legal certainty clear regulation market new well medicine handle datum roche currently develop monitor app people worry datum misuse parkinson disease roche break new technology generate uncertainty app business look debate genetic engineering prefer sell medicine current debate concern parkinson disease app associate datum misuse playing similar line app concern justify need take company develop suitable one seriously manage important negativity dominate equation genetic diagnostic engineering technology ban diagnostic undergo sea change achievement life science industry business model sell instrument possible test customer interpret data medicine produce biotechnology offer clinical decision support mean aggregate data system patient benefit genetic engineering supply relevant decisionmake gain digitalisation information doctor patient like thing new well medicine navify tumor board building digital realworld datum enable connection ecosystem thirdparty company classical clinical trial datum able dock provide app give example spot new therapeutic target genuinely new business model molecule identify different subgroup patient population consequence develop roche position datum protection new medicine specific effective concept datum need protect way second medicine reach market dna put data protection fast design clinical trial practice clinical trial decade regularly efficiently accelerate approval process find government agency hospital finally digital decisionmake aid help willing partner solid treatment target efficient expertise protect patient datum trust lot everyday clinical practice help patient need advantage lead improve healthcare roche trust give substantially accelerate digitalisation put fast track medical advance data volume achieve personalise healthcarecorporate executive committee roche corporate executive committee dr stephan feldhaus head group communications dr alan hippe chief financial officer dr william pao head roche pharma research early development pre dr james h sabry global head pharma partner dr michael varney head genentech research early development gre dr severin schwan ceo roche group daniel oday ceo roche pharmaceutical cristina wilbur head group human resources dr michael heuer ceo roche diagnostic dr gottlieb keller general counsel member enlarge corporate executive committee roche corporate executive committee december midst roche apprenticescorporate executive committee roche business performance roche roche show strong business performance uptake new medicine continue strong year stringent quality control ensure product provide patient meet respective production criterion strong result division strong growth new product characterise year base performance roche position future growth group sale rise chf billion international region sale grew lead core operating profit increase reflect asiapacific latin america subregion japan strong underlying business performance core ep sale decline government price cut grow ifrs net income increase biosimilar competition include benefit tax reform high net financial income diagnostic division sale increase chf billion centralised point care sale pharmaceutical division increase solution main contributor lead chf billion key growth driver growth immunodiagnostic business new medicine ocrevus treat form sale increase business area regional term multiple sclerosis ms cancer medicine growth drive asiapacific north perjeta tecentriq alecensa hemlibra treat america sale increase emea haemophilia expect strong uptake latin america japan newly introduce medicine partially offset low sale mabtherarituxan tarceva drug approval expedite review food drug administration fda sale increase lead ocrevus perjeta grant approval include tecentriq lucentis europe sale affect combination avastin paclitaxel carboplatin competition biosimilar mabtherarituxan chemotherapy initial treatment people herceptin partially offset metastatic nonsquamous nonsmall cell lung strong launch new medicine ocrevus cancer nsclc egfr alk genomic tecentriq alecensa perjeta tumour aberration mabtherarituxan forbusiness performance roche material topic cover chapter product portfolio strategy growth strategy emerge develop market pemphigus vulgaris avastin form ovarian roche diagnostic introduce new product cancer hemlibra people haemophilia service announce key partnership factor viii inhibitor xofluza baloxavir marboxil treatment acute uncomplicated strategic partnership ge influenza people aged year old healthcare combine vitro diagnostic ge healthcares vivo expertise european medical agency ema approval codevelop comarket decision support software include ocrevus ms hemlibra people solution anchor share digital platform haemophilia inhibitors factor viii design allow party potentially perjeta adjuvant treatment herpositive early place product companyagnostic breast cancer high risk recurrence application china national drug administration approve navify clinical trial match navify alecensa treatment alkpositive nsclc publication search app launch app scan globally renowned resource fully fda grant priority review tecentriq plus integrated navify tumor board chemotherapy albuminbound paclitaxel initial firstline treatment unresectable locally viewic inc datum analytic platform advance metastatic triplenegative breast cancer launch solution applicationsviewic tnbc people disease express pdl labops viewic dx optimizationto support protein determine pdl biomarker test well productivity decisionmake clinical care laboratory hospital health authority eu japan grant expedite review entrectinib cobas pro integrate solution serum work area solution medium lower highthroughput ema grant prime designation rg laboratory launch country accept treatment huntington disease ce mark investigational oral medicine risdiplam treatment people spinal muscular atrophy outlook sale expect grow low midsingle diagnostic datum management digit range constant exchange rate core earning decision support share target grow broadly line support healthcare provider need manage sale constant exchange rate roche expect evergrowing amount datum diverse source increase dividend swiss franc growth rate report constant exchange rate cer average food drug administration prescribing information perjeta emea europe middle east africa diagnostic division sale product service roche diagnostic support healthcare provider transform datum actionable insight help laboratory world succeed increasingly complex rapidly change healthcare environment sale diagnostic division grow strongly business grow respectively continued chf billion growth report high demand report cobas liat test region business area new system molecular pointofcare test regional growth lead emea north centralise point care solution america large contributor division sale growth serum work area solution comprise cobas dry blood spot test qualitative early immunodiagnostic clinical chemistry infant diagnosis cobas plasma separation businesse main growth driver card quantitative viral load testing use centralise point care solution business cobas launch improve access expand especially asiapacific sale hiv diagnosis remote area growth china north america tissue diagnostic sale increase advanced cobas pro integrate solution serum work area stain business continue strong growth solution medium low highthroughput demand primary stain portfolio high laboratory launch country accept regionally growth lead north america ce mark emea growth asiapacific drive china sale molecular diagnostic increase virology sale sale blood ventana dp slide scanner launch screen human papillomavirus hpv early create highquality tissue slidebusiness performance roche north america europe middle east africa emea japan latin america asiapacific asiapacific region division main growth driver image offer pathologist digital image topselle product portfolio chf million accurately reproduce see microscope image serve basis menu image analysis algorithm currently development roche launch upath cobas enterprise software universal digital pathology immunodiagnostic software application lab administrator histotechnician pathologist enable pathologist patientcentric case view quick diagnosis cobas clinical chemistry diabetes care sale increase mainly drive new accuchek guide accuchek instant system sale growth report north america latin america asiapacific ventana advance stain launch pilot market new accuchek solo micropump receive encourage customer feedback enhance positive acceptance visible integrate diabetes management solution include cobas mysugr virology accuchek diabetes care growth rate report constant exchange rate cer average deliver medical value digital world era digital technology increasingly future menu roche image analysis algorithm able tailor medical treatment need scanner cemarke vitro diagnostic use individual far information capture available research use store analysed revealing disease manifest patient experience october officially open new manu day day deepen understand molecular facture site rd centre suzhou china science new diagnostic tool datum support future diagnostic need china management method bring disruptive change region regional headquarters singapore patient care exist branch china major healthcare provider asiapacific holistic approach digital transformation rapid population growth couple change extend technology address entire landscape highend manufacturing encourage customer experience encompass product expand global manufacturing expertise portfolio result new way work locally roche diagnostic transformation business underway enable leader transform datum actionable insight digital diagnostic remain global leader decision support vitro diagnostic medical knowledge increase exponential rate healthcare provider need manage large provider realworld grow amount datum diverse source datum produce billion test result year electronic health record doctor note clinical total exceed billion result trial diagnostic instrument digital technology datum initiative underway committed deliver roche understand confident decision digital solution servicesin addition make clinical practice happen human industryleade diagnostic portfoliothat offer medical knowledge digital medical knowledge enhance broad customer experience help come seamlessly diagnostic improve live patient world pharmaceutical division work roof combine profound understanding march launch ventana dp high disease diagnostic treatment uniquely speed slide scanner digital pathology unique position tackle challenge vast complex traybase design enable notouch slide processing source datum work external reduce workflow error provide reliable high partner develop new solution speed scan histology slide excellent good use datum enable smart efficient image quality reliability set new standard research development well patient care digital pathology provide foundation overallbusiness performance roche industryleade portfolio integrate diagnostic solution grow significantly product launch europe early roche diagnostic ge healthcare integration imaging imaging analytic announce agreement enter strategic mean product capable integrate partnership combine vitro diagnostic roche vitro diagnostic datum eg biomarkers tissue ge healthcares vivo expertise codevelop pathology genomic vivo diagnostic datum comarket decision support software solution provide ge healthcare eg medical imaging anchor share digital platform design patient information allow party potentially place product companyagnostic application initial focus september launch navify clinical oncology acute care decision support app underline strategy mark step personalised continue develop navify decision support healthcare navify clinical trial match navify portfolio launch help multidisciplinary publication search app scan globally renowne care team navigate increasingly complex medical resource fully integrate navify information commercially available tumor board app represent start productnavify tumor boardis cloudbase navify app ecosystem app roche software solution fundamentally change partner party follow way oncology care team prepare conduct document clinical treatment decision viewic inc datum analytic platform launch solution application support ge healthcare introduce well productivity decisionmake clinical care navify tumor board v offer deep laboratory hospital test hour roche integrate core lab icl vastly expand efficiency scope quality diagnostic capability laboratory industryleade portfolio integrate diagnostic solution grow significantly product launch europe february receive fda clearance cobas factor ii factor v test cobas system provide rapid workflow aid diagnosis patient suspect thrombophilia test enable laboratory simultaneously assess factor ii factor v gene mutation single patient sample reduce handson time testing patient cobas pro integrate solutionsstarting point new generation serum work area inherit thrombophilia test expand solutionsseamlessly integrate roche integrate core lab current menu cobas system enable lab consolidate genomic oncology microbiology virology testing single platform new test complement recent ce approval cobas october viewics labops application roll cobas coagulation analyser central customer region asiapacific lab make roche key partner laboratory follow soon viewic labop offer easytouse perform coagulation thrombophilia testing dashboard report datum customer efficient test design allow laboratory report lab hospital operation viewic dx optimization patient samplesand resultsper minutes module feature suite dashboard report design optimise physician order protocol april receive k clearance premarket available canada submission fda cobas ctng assay use cobas system empower laboratory innovation direct detection chlamydia trachomatis ct efficiency andor neisseria gonorrhoeae ng dna enable continuous access advanced symptomatic asymptomatic individual innovative diagnostic help laboratory cobas ctng assay help lab handle increase world succeed increasingly complex testing volume highestthroughput solution rapidly change healthcare environment currently marketbusiness performance roche july fda grant breakthrough device hour continuous loading supply designation elecsys amyloid csf furthermore offer simplicity automate elecsys phosphotau p csf tests maintenance calibration feature vitro diagnostic immunoassay measure broad swa assay menu consolidate single amyloid phosphotau concentration platform short assay incubation time low cerebrospinal fluid csf adult patient sample volume requirement cognitive impairment evaluate alzheimer disease ad cause dementia diabetes care business implement diagnosis ad largely base clinical strategy offer integrate diabetes management symptom include cognitive testing solution connect physical product include significant number patient diagnose blood glucose meter test strip digital disease advance biomarkerbase solution service july receive testing expect lead great diagnostic cemark accuchek solo micropump certainty contribute search effective begin launch market treatment create open ecosystem product solution include thirdparty solution nextgeneration sequence ng portfolio sign important datasharing agreement continue grow october new ng novo nordisk senseonics june avenio tumor tissue analysis kit launch enter collaboration agreement care globally researchuseonly ruo kitsthe innovation telehealth solution provider avenio tumor tissue target kit expand kit agreement care innovation customer base surveillance kitdetect mutation canada offer mysugr class solid tumour complement ngs app allow people diabete receive ctdna kit oncology research avenio ruo advice certify diabetes educator customer portfolio readytouse kit provide reagent accuchek guide blood glucose software need lab determine genomic meter test strip deliver directly characteristic solid tumour single home dna workflow integration insulin dosage continuous december launch cobas pro integrate glucose monitor datum digital solution solution laboratory medium high include mysugr help create insight base throughput serum work area swa test datum personalise solution aim improve new generation swa solution offer high level therapy outcome patient benefit efficiency throughput test healthcare professional payer toobusiness performance roche ilka gdanietz mysugr austria long impact imagine type diabete live nowadays wear pump constantly deliver age diabetes datadriven disease insulin body implant sensor handle number day like skin send glucose reading blood glucose level carb intake calculate real time smartphone smartwatch right insulin unit list connect app mysugr go person live diabete store relevant diabetes data place therapy decision day let know detect certain pattern suck exhaust blood glucose reading need pay timeconsume frustrating extra attention work mysugr mysugr expect healthcare industry aim offer allround care people diabete development product service open app solution specialise coach alive life easy automate datum track mysugr hopefully good quality life roche group work convince digitalisation big role help living diabete burdensome play understand pain coworker live type diabete develop active role raise awareness feature app account practical condition write issue life get view bestknown diabetes blog germany patient board early stage goal get increasingly involve patient away therapyrelate task possible advocacy colleague moderate patient diabete patient event year draw participant grow diabete day blood glucose meter big test take living diabetes work company focus minute insulin shot diabete spend free time time day addition handwritten diabetesrelated project advocacy sound logbook record mess time bit weird long impact change diabetes care imagine digital transformation happen pharmaceutical division sale total sale chf billion year key market ocrevus successful new product launch roche history sale pharmaceutical division increase sale grow international chf billion new medicine contribute region particularly china growth actemraroactemra rheumatoid herceptin perjeta kadcyla combine arthritis form juvenile idiopathic arthritis herpositive breast cancer herpositive giant cell arteritis car tcellinduce metastatic gastric cancer herceptin herceptin severe lifethreatening cytokine release syndrome sale increase mainly drive growth sale increase region drive china europe japan sale affect biosimilar xolair chronic idiopathic urticaria allergic asthma growth drive avastin advanced colorectal breast lung demand indication kidney cervical ovarian cancer relapse glioblastoma type brain tumour sale increase lucentis eye condition international region include neovascular wet agerelate macular japan decline europe degeneration macular oedema follow retinal vein occlusion diabetic macular oedema diabetic mabtherarituxan form blood retinopathy growth drive sale prefille cancer rheumatoid arthritis certain type syringe sale increase approve vasculitis sale development impact europe indication japan biosimilar competitionbusiness performance roche key growthdriver chf millions herceptin oncology avastin oncology highlight medicine launch perjeta herpositive breast cancer sale chf billion grow region december perjeta register country perjeta adjuvant treatment indication strongly oncology support continue growth drive increase demand adjuvant ebc neoadjuvant metastatic setting europe ocrevus ocrevus chf billion treatment neuroscience relapse rms primary progressive ppm form ms growth drive new patient patient request followup therapy alike actemraroactemra esbriet chf billion idiopathic immunology pulmonary fibrosis ipf sale continue expand drive growth tecentriq chf million advanced xolair bladder cancer advanced lung cancer initial immunology therapy nonsquamous nsclc growth drive postlaunch uptake europe launch japan alecensa chf million alkpositive esbriet nsclc alecensa show continue strong sale immunology growth region gazyvagazyvaro chf million chronic lymphocytic leukaemia cll rituximab kadcyla refractory follicular lymphoma previously oncology untreated advanced follicular lymphoma sale expand especially europe hemlibra chf million hemlibra approve tecentriq people haemophilia inhibitor oncology factor viii country include eu australia japan hemlibra approve people haemophilia factor viii inhibitor country alecensa oncology growth rate report constant exchange rate cer average rejuvenating portfolio new option patient result phase iii alex jalex study new medicine include ocrevus perjeta alecensa add wealth evidence tecentriq alecensa hemlibra see continue support firstline use alecensa multiple strong uptake multiple market patient population alkpositive nsclc follow rapid worldwide regulatory sale chf billion year approval recently announce result key market ocrevus successful headtohead phase iii alesia study alecensa versus new product launch roche history addition crizotinib asian patient population alk meet extremely positive response positive advanced metastatic nsclc reinforce new market vast majority finding alex jalex study show patient form return followup reduction risk disease worsen death treatment twiceayear medication strong alecensa lower risk tumour spread demand indication continue fiveyear growth brain central nervous system datum show efficacy ocrevus maintain key measure disease activity people ms treat early ocrevus superior alecensa approve china alk disability progression outcome compare rm positive advanced nsclc month patient switch interferon betaa approval europe ppm patient switch placebo long term safety datum continue favourable risk strong datum announce tecentriq benefit profile study triplenegative breast cancer tnbc extensivestage small cell lung cancer ocrevus approve country people treat globally positive result announce phase iii december impassion study tecentriq plus chemotherapy nabpaclitaxel initial firstline treatment perjeta represent major advance treatment unresectable locally advanced metastatic tnbc patient breast cancer generate total sale positive phase iii immunotherapy study chf billion launch usage continue tnbc aggressive disease limit treatment broaden study result confirm medical benefit option tecentriq chemotherapy combination additional indication include result significantly reduce risk disease worsen phase iii aphinity study adjuvant treatment death progressionfree survival pfs compare herpositive early breast cancer patient chemotherapy intentiontotreat high risk recurrence pdlpositive population subgroup determine phase iii openlabel extension study opera opera ii oratorio zhou c et al primary result alesia present esmo congress munich germany abstract lbabusiness performance roche europe japan international eastern europe middle east africa latin america asiapacific canada form international region pdl biomarker testing show treatment haemophilia hemlibra encourage overall survival benefit pdl gain fda approval people positive population interim analysis haemophilia factor viii inhibitor previous approval new medicine positive result phase iii impower indicate haemophilia patient study tecentriq plus carboplatin etoposide dose regimen subcutaneous chemotherapy initial firstline treatment treatment weekly week people previously untreate extensivestage week datum study small cell lung cancer show tecentriq support approval review chemotherapy help people live significantly european medicine agency long compare chemotherapy intentiontotreat population combination result kadcyla phase iii katherine study base tecentriq significantly reduce patient herpositive early breast cancer risk disease worsen death compare ebc show treatment kadcyla single chemotherapy agent lead significant reduction risk disease recurrence death compare herceptin hemlibra approve people haemophilia adjuvant surgery treatment people inhibitor factor viii country herpositive ebc residual disease present approval transform medical practice follow neoadjuvant surgery treatment approval expedite review december fda approve tecentriq biologic therapy approve combination avastin paclitaxel carboplatin fda pemphigus vulgaris major chemotherapy initial firstline treatment advancement treatment disease people metastatic nonsquamous nonsmall cell year lung cancer nsclc egfr alk genomic tumour aberration additionally approval grant fda subcutaneous formulation actemra october fda approve xofluza roactemra form juvenile idiopathic arthritis treatment influenza infection xofluza avastin form ovarian cancer firstinclass singledose oral medicine novel propose mechanism action approve expedite review status treatment acute uncomplicated influenza people fda grant priority review status tecentriq aged year old demonstrate efficacy plus chemotherapy nabpaclitaxel initial wide range influenza virus include firstline treatment unresectable locally advanced oseltamivirresistant strain avian strain hn metastatic tnbc people disease express hn nonclinical study pdl protein determine pdl biomarker testing july fda grant breakthrough fda grant approval mabthera therapy designation tecentriq combination rituxan treatment adult moderate avastin firstline treatment people severe pemphigus vulgaris rare life advanced metastatic hepatocellular carcinoma threaten condition characterise progressive base ongoing phase ib study imbrave painful blister skin mucous membrane phase iii study ongoing european medicine agency ema grant prime priority medicine designation company investigational medicine rg know ionishttrx treatment people huntington disease investigational oral medicine risdiplam rg treatment division growth drive new product people spinal muscular atrophybusiness performance roche chf million divisional sale erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq venclextavenclyxto ocrevus hemlibra xofluza venclextavenclyxtos sale book partner abbvie percentage sale contribution medicine launch increase steadily entrectinib grant expedite review live cancer patient make optimal use status major regulator fda healthcare data analytic partnership breakthrough therapy designation eu ema leverage combine expertise advance prime designation japan japanese ministry use realworld evidence set new industry health labour welfare sakigake orphan standard oncology research development drug designation entrectinib development treatment ntrk fusionpositive locally late july roche complete transaction advanced metastatic solid tumour adult ownership foundation medicine paediatric patient cancer progress inc fmi transaction accelerate follow prior therapy acceptable comprehensive genomic profiling oncology standard therapy make fmis highquality comprehensive genomic profiling test innovative data service advance personalise healthcare commonly available company april roche complete acquisition leverage expertise genomic molecular flatiron health acquisition help combine information enhance development person effort company commit improve alised medicine care patient cancer image touch yetbusiness performance roche gehad refky roche egypt partner life get know month old doctor tell go degree pharmacy parent haemophilia imagine biotechnology year ago join roche day work able work different area rheumatoid help like personal experience arthritis anaemia transplantation year advantage importantly responsibility ago complete chance read article challenge person haemophilia roche develop medicine call emicizumab know burden disease hemlibra haemophilia company nuisance debilitate hope work medicine day complication finally position product manager open apply honestly little child aware haemophilia affect family work launch team emicizumab diagnosis come twisted roche egypt hope medicine ankle bleed inside turn shade available patient soon busy team purple green grow understand prelaunch activity education need careful carry programme healthcare professional spread routine daytoday task nightmare awareness haemophilia talk bleed episode physician patient group emicizumab occur inconvenient time parent search hospital doctor fearful life make easy explain burden inject familiar disease challenge patient face daily life field visit school difficult time varied medical science liaison conversation experience toughen remember medical expert move different level break leg twisted ankle time come know disease skip morning line recess haemophilia partner life get month child look strangely know hope use think give special privilege benefit othersscience innovation roche core business science innovation advance digital technology datadriven analytic increasingly shape research development go forward take personalise healthcare level employee prepare sample roche digital pathology platform key asset programme cancer immunotherapy data insight well inform decision machine learning tool identify pattern morphological change bacteria tightly link antibiotic mode action moa provide unique fingerprint new technology advanced analytical tool roche building wideranging expertise help manage sense large combine strength pharmaceutical fastgrowe dataset emerge powerful diagnostic past year catalyst transformation healthcare company universally acknowledge pioneer term accelerate research development rd leader wave personalise healthcare ensure access well possible care patient phc effort company develop target treatment start concrete example tremendous progress breast cancer medicine herceptin recent year wearable device smart phone app continuous patient monitoring access go forward ability capture understand affordable wholegenome sequence technology unprecedented amount data multiple source machine learn capability reveal allow high resolution indepth hide secret medical image new tool view patient put promise truly technologie increasingly unlock value personalise healthcare reach physician intent identify good possible therapy option patient draw unique combination strength regulator request solid outcomebase datum pharma diagnostic capability realworld setting roof lead portfolio therapy wealthscience innovation roche material topic cover chapter product portfolio strategy rd pipeline strategy personalise healthcare expertise medicine biology world viral diversity susceptibility drug lead company foundation medicine hbv infection common world flatiron global reach culture nearly million people chronically infect successful partnership deeply commit million live china direct deliver meaningful sustainable value result infection hbv sizeable patient healthcare system go forward number individual develop hepatocellular carcinoma deadly form power new possibility advance cancer analytic able create wealth new data insight opportunity entire product vaccination highly efficacious prevent lifecycle rd value chain make infection vaccine coverage incomplete ongoing informed choice biological target mothertochild transmission contribute pursue research innovate optimise continued propagation disease design clinical trial ultimately improve current hbv treatment effectively suppress viral patient access right drug right time roche replication typically curative leverage powerful new high unmet medical need curative tool cusp wave phc hbv therapie ultimate goal equip physician tailormade solution patient research show hbv high mutation rate previously think surprisingly short optimise drug design closeup view viral period time virus effectively sequester heterogeneity bacterial behaviour human cell replication machinery order historically roche pioneer proliferate billion virus day powerful presence infectious disease area possible mutation represent prominent example roche product space antiviral invirase hiv pegasys hepatitis c modern stateoftheart ultradeep sequence tamiflu xofluza influenza antibacterial mutant viral strain quasispecie bactrim rocephin pneumonia urinary tract characterise precisely purpose roche infection etc collaborate medical centre nether land china obtain representative viral sample roche currently develop broad portfolio different population part world innovative potentially transformative medicine sample reveal variant include directacting antiviral immuno modu viral surface antigen lator treat infection hepatitis b virus hbv new antibacterial staphylococcus apply random forest modelling wellknown aureus multidrugresistant gramnegative machine learn tool datum possible bacteria interlink deep genomic sequence datum information viral behaviour patient clinical project roche scientist start apply feature characterisation hbv genome sublethal concentration number compound predict viral genetic feature different antibiotic class culture clinically relevant people chronic hbv escherichia coli induce change key bacterial infection guide drug development effort parameter membrane integrity cell shape individual treatment approach dna intensity visible fluorescence microscopy exact pattern change tightly link machine learn antibiotic research moa provide unique fingerprint grow public health threat make frequent headline medium antimicrobial resistance machine learn perfect tool find amr refer fact antibiotic similarity pattern large dataset meaningful increasingly lose effectiveness broad conclusion similarity morphological range common difficulttotreat bacterial change rarely draw merely look image infection microorganism acquire resistance acquire microscope antibacterial drug problem widespread apply appropriate image analysis tool especially trouble gramnegative bacteria quantify change different project cause million death morphological parameter machine learning annually determine profile change unique match know antibiotic novel view press medical need new information hand roche scientist uncover antibiotic novel mode action roche unique signature prioritise bacterial pathway reentere space focus gram guide drug discovery effort negative bacteria like acinetobacter baumannii identification moa machine learn pseudomona aeruginosa number provide important information support compound preclinical development target antimicrobial drug development effort aim develop antibiotic active prioritise compound good potential diseasecausing multiresistant infection development new antibiotic crucial understand precise mode action moa genomic profile digital biomarker innovate compound inhibit bacterial growth clinical trial benefit patient roche apply innovative machine healthcare datum generate learn technique large imagebase dataset world grow exponential rate sheer help inform drug discovery development volume medical information double project require intense inhouse multidisciplinary month example detailed investigation collaboration expert area antibiotic cancer molecular level help research microscopybase cellular assays gene comprehensive genomic profiling continuous expression profile informatic focus monitor disease progression neurodegenerative statistic machine learn tool image condition help smartphonebase sensor analysis produce billion datum point antimicrobial resistance tackle crisis health wealth nation london wellcome trust science innovation roche cupisco trial study design standard chemotherapy treatment option molecular tumour board alk ret alecensa treatment decision egfr avastin tarceva randomisation herceptin perjeta ptch smo erivedge molecular profiling braf cotellic zelboraf tissue blood responder brcaparp parpi aktpik ipatasertib cycle tmb high tecentriq chemotherapy nonresponder tmb intermlow chemo tecentriq actionable alteration molecular tumour board treatment decision primary endpoint progressionfree survival secondary endpoint overall survival cupisco study compare efficacy safety target therapy cancer immunotherapy guide genomic profiling versus chemotherapy patient cancer unknown primary site tool technology generate vast median overall survival cup patient abysmally amount datum valuable nugget lowin range yearso information extract offer urgent medical need well therapy deep insight nature diverse disease provide exciting new opportunity granular information question drug discovery development mutation drive cup urgently need cancer cause mutation come term cancer unknown primary host different genetic factor require decade tremendous comprehensive genomic profiling progress comprehend treat cancer cupisco come play understand cancer biology molecular level lead development target effective cupisco phase ii randomise clinical study therapy recently cancer immunotherapy recruit histologically confirm cup base improved knowledge tumour patient country eventually total immunology show impressive clinical result participant number approve roche cancer hand cancer unknown primary medicine study trial study site cup devastate diagnosis compare efficacy safety target therapy approve treatment available cancer immunotherapy versus chemotherapy cancer diagnose fall category mean primary endpoint progressionfree survival tumour metastasis detect ground break study represent shift away possible find originate tumour treat cancer base organ origin foundation medicine genomic profiling report clinical finding convert specific treatment decision unprecedented clinical trial set potential pave way truly target personalise treatment strategy understand individual patient journey multiple sclerosis live multiple sclerosis ms make unpredictable uncertain existence treatment advance need understand disease order improve outcome patient despite advance imaging ability measure roche conduct research programme create people ms well understand disease change decade individual disease course usually base visit clinic place twice year provide limited snapshot mean populationlevel understand ms good knowledge treat base clinically relevant genomic individual patient journey ms alteration drive cancer growth end roche collaborate foundation medicine world roche create floodlight research programme lead molecular insight company matching design smartphonebase test patient unique genomic profile know therapy potential monitor disease daily basis clinical trial parameter measure coordination mobility information processing speed addition perform thorough molecular mood neurologist pocket programme workup patient virtual molecular include floodlight open roche open tumour board bring oncologist access study enrol data radiologist surgeon pathologist health point person contribute unique care professional set cupisco open dataset design help ms research study discuss result patient individual forwardscience innovation roche detect progression disease early nmp clinical ng report software quantifiable manner significant innovation solution richly curate uptodate ms community addition further knowledge base genetic variant design help understand ms improve individual lab accurately efficiently interpret clinical patient care hope accelerate drug significance mutation identify therapy development improve ability bring new option clinical trial match design drug market fast efficiently lab want ng test inhouse need robust clinical reporting solution expand identify clinically actionable variant available navify portfolio clinical clinical lab look offer nextgeneration decision support software eg navify tumor board sequence ng cancer testing challenge nmp simplify analysis complex complexity analysis report ng datum aid lab identify reporting difficulty encounter accurately assess clinically actionable somatic mutation clinical significance genomic variant inform sophisticated software integral optimal clinical treatment option base good navify decision support portfolio suite practice realworld evidence cloudbase workflow solution app streamline clinical workflow integrate patient datum differentiate benign pathogenic variant multiple source help access relevant small feat classifying degree knowledge support treatment decision actionability pathogenic variant underpin clinical decision term appropriateness partner success cancer treatment option challenge grow complexity healthcare couple require review multitude public source explosion datum multiple siloe guideline properly interpret clinical source mean future medicine build significance decide course action partnership single stakeholder able shape view roche develop clinical decision require new way partner collaborate support solution call navify mutation profiler nmp traditional boundary internally plan launch early enable externally roche expand diagnostic lab overcome great challenge collaborative effort increasingly combine clinical ng workflow translate rich resource unique tool complex dataset actionable treatment option technology partner combine vivo vitro diagnostic create software integrate early roche ge healthcare announce fragmented clinical molecular genomic real enter longterm strategic alliance world datum treatment plan health outcome develop industryfirst digital platform software combine platform roche wide solution marry vivo vitro diagnostic range oncology expertise collaboration set insight allow seamless integration push phc new level cancer analysis comprehensive clinical decision patient healthcare provider support solution navify tumor board roche syapse collaboration comprise key global strategic partnership offer physicians objective develop precision medicine insight comprehensive datum dashboard pull product generate realworld evidence support information image ct mri scan accelerate access innovative therapy blood test tissue sample gene sequence plus syapse clinical application create evidence late clinical trial precision medicine programme enable health economic outcome research build patient alliance help accelerate delivery datum report outcomes programme understand drive phc care team patient healthcare precision medicine effect healthrelate quality industry apply advanced analytic vivo life accelerate enrolment clinical trial datum ge healthcare medical imaging match eligible patient trial partnership monitoring equipment vitro datum syapse complementary ongoing roches biomarker tissue pathology sequence effort flatiron health company address portfolio goal jointly develop comarket distinct healthcare system provider clinical decision support software fast network accurate decisionm ake clinician enable early diagnosis individualised treatment patient syapse network comprise million cancer patient nearly hospital south collaborate phc progress cancer korea cover newly diagnose cancer january roche enter collaboration patient strong network add agreement san franciscobased syapse key roche effort bring novel therapy patient player healthcare form syapse fast include accelerate regulatory filingsscience innovation roche harness frontline scientific technology gene therapy offer hope patient choroideraemia rare disease eye lead complete blindness roche research organisationspre roche bet gene therapy rare eye disease pharma research early development gred choroideraemia rare monogenic recessive retinal genentech research early developmentare disease cause mutation specific gene affecting pioneer new way tackle challenging disease male progressive peripheral condition high unmet medical need vision loss night blindness usually patient teen year culminate common activity relentless effort complete blindness later life understand underlying disease biology molecular level identify relevant gene therapy hold key alleviate biomarker help find right patient condition gene therapy therapeutic gene target treatment right time ultimate goal specific segment dna introduce target develop compound zero intended cell order replace miss faulty gene biological target perfectly druglike property example mutant chm gene fail properly tolerate highly effective encode fully functional protein number highlight gene therapy traditionally face real challenge innovative rd programme area find effective gene delivery vehicle ophthalmology oncology immunology vector fulfil intend purpose satisfactorily highly optimise thirdgeneration adeno open new avenue cancer immunotherapy associated virus aav vector perfect roche invest develop great vehicle gene transfer locate innovative treatment option help person enter specific cell high degree precision immune system fight cancer building approve cancer immunotherapy cit tecentriq company molecular therapeutic development programme take comprehensive dmt forefront aav technology approach pursue goal restore cancer choroideraemia lend particularly immunity pioneer modality announce expand longterm partnership dmt profound understanding underlie april roche enter new terrain science cit extensive experience engineering choroideraemia project foray gene new sophisticated modality unique therapy position drive forward development new potentially firstinclass cancer immunotherapy key advantage aav invent dmt benefit patient treat choroideraemia mode application intravitreal injection intravitreal application stimulate immunity target way avoid risk retinal detachment checkpoint inhibitor cpis tecentriq involve surgery case traditional able remove brake inhibitory pathway subretinal application furthermore immune system resume attack modality possible reach retina tumour cell contrast mode action inject functional working chm gene investigational medicine fapilv work eye aav ability penetrate stimulate immune system fapilv vitreous space access entire retinal target tissue work synergistically cpis efficacy include photoreceptor majority patient respond stop respond genetic retinal disease occur high hope aav gene therapy fapilv homegrown roche molecule prove great value people affect part highaffinity antibody choroideraemia roche prepare direct fibroblast activation protein fap investigational new drug ind submission find wide variety cancer cell fda order soon start human trial solid tumour blood cancer space second ilv engineer form ilscience innovation roche increase diligence awareness man affect choroideraemia symptom usually patient teen year cytokine protein involve activation cell prevent surface protein immune system intravenous infusion call tigit bind pvr specific receptor monoclonal antibody portion recognise bind tumour cell fap concentrate ilv fapexpresse tumour tissue ilv portion stimulate immune tumour cell impair ability response activate natural killer cell attack cancer cell expression inhibitory cytotoxic cell fight cancer receptor surface exhausted tigit express surface exhausted cell roche scientist engineer ilv way similar pd hamper tigit interaction retain powerful immunestimulate property receptor pvr goal help remove il simultaneously display reduce additional brake exhausted cell activity cell dampen antitumour immune reactivate attack tumour response design long tiragolumab novel checkpoint inhibitor provide halflife superior riskbenefit profile compare add activity tecentriq especially normal il bind fap lead inflame tumour high pdltigit expression buildup fapilv concentration tumour tissue application immune modulator allow specifically tigit regulate activate long activation high concentration fap receptor surface cell cd tigit express tumour express surface cell limit activation cell disrupt cd function fapilv investigate phase iib scientist create antibody phase ii study number cancer type block tigit bind pvr way free renal cell cancer nonsmall cell lung cancer cd bind pvr instead consequently turn combination therapy eg tecentriq green light block tigit remove brake allow activate remove brake turn green light molecule signal tiragolumab good novel cancer immunotherapy agent monoclonal safety profile single agent combine antibody tiragolumab develop record speed tecentriq patient currently enrol genentech scientist research clinic randomised phase ii non mall cell lung cancer help revive tumourfighting ability proofofconcept study researcher pioneer cuttingedge technology address challenging disease high unmet medical need advance medicine people immune circulate autoantibody produce b cell disease inflammatory cytokine protein generate recent advance understand immune myeloid cell chronic spontaneous urticaria pathway guide research activity inflammatory csu highly debilitate skin disease auto autoimmune disease insight help yield immunity know play role new target new treatment new way think patient vital capability address disease high unmet medical need disease current standard care antitumour necrosis factor ra immuno blocking driver autoimmune disease sup pressant sle antihistamines csu fail rheumatoid arthritis ra systemic lupus achieve sustained remission relieve symptom erythematosus sle occur immune majority patient system begin attack organ tissue significant unmet need novel therapeutic condition characterise increase improve efficacy low toxicityscience innovation roche bruton tyrosine kinase btk protein fibrotic disease process ultimately lead identify key activator b cell cirrhosis liver failure immune cell type myeloid cell btk play important role development proliferation silent liver disease symptom immune cell type btk blockade likely develop people metabolic represent opportunity treatment disorder type diabete dyslipidaemia broad range autoimmune disease ra sle obesity currently approve therapy csu condition obvious need effective treatment scientist genentech face daunting task design btk inhibitor right combination improve situation potency specificity stability take fibroblast growth factor fgf member year hard work achieve feat finally metabolic fgf family express primarily researcher find investigational small molecule liver regulate fat metabolism potent offer target approach modulate b cell mobiliser fat liver find way target myeloid cell intend manner pathway highly specific manner hold key treatment space molecule fenebrutinib currently clinical trial highly potent base insight genentech scientist create selective orally administer reversible non antibody molecule mimic fgf signal covalent inhibitor btk base attribute hypothesis compound expect acceptable safety profile remove socalled insult fat accumulation phase ii study ra recently meet primary nash liver halt reverse inflammatory endpoint superior efficacy placebo data fibrotic process restore healthy liver function disclose conference lupus base deep understanding fgf receptor csu phase ii study ongoing expect biology scientist design bispecific antibody complete act fgf hormone mimetic receptor hormone combination heterodimer target hormone halt liver damage different protein fgfrc klb bispecific nonalcoholic steatohepatitis nash fibrotic antibody target ideally suit liver disease drive accumulation excess generating longacte safe drug fat liver trigger inflammatory desire receptor selectivity antifgfr antibodie develop cancer injury intestinal system digestive therapy act inhibit fgfr pathway tract result chronic inflammation pattern prevent unwanted cell replication fgfrklb mucosal ulceration surface intestinal signal fgf proliferative mediate wall injury elicit hyperinflammatory beneficial metabolic signal specifically response immune system standard treatment activate fgfrklb pathway activate consist immunosuppressive drug fgfr addition target metabolic antitnfs drug combat disease symptom signal tissue express heterodimer block immune response reduce adipose tissue molecule complete inflammation multipled ose phase ib study obese patient nonalcoholic fatty liver disease precursor nash genentech scientist come alternative idea base dual functionality il instead unique potential harness fgf biology suppress immune system order alleviate reduce liver fat deposition fgfrklb symptom aim root cause ibd bispecific antibody beneficial effect promote regenerative protective function parameter insulin triglyceride il epithelial tissue potentially cholesterol able provide healing disease achieve longterm metabolic health benefit new medicine represent firstinclass disease modifying truly transformative therapy ibd nonimmunosuppressive therapy patient inflammatory bowel disease cytokine interleukin il important fact il long history company component immune system play key cytokine cell receptor discover role wound injury occur fact il genentech scientist early dual mechanism action set establish biology il help restore repair epithelial cell wall scientist engineer new modality recombinant line skin internal organ fusion protein ilfc link carefully modify colon second help fight bacteria part il unique dual mechanism enter site injury cause infection action customise fusion protein promote production nonimmunosuppressive therapy disease antimicrobial peptide area design block il signal apply phase ii clinical study inflammatory bowel disease ibd crohns getting start investigate safety efficacy disease ulcerative colitis uc associate ilfc ibdscience innovation roche pharmaceutical clinical pipeline breakthrough therapy designation year phase phase li phase ill registration oncology inflammation immunology neuroscience infectious disease ophthalmology pipeline new molecular entity cover broad range disease highly innovative technology apply create produce active molecule importance intellectual property innovation continue innovation key provide new improved therapy crucial patient longterm commercial success patent intellectual property right provide time limited exclusivity innovation enable substantial investment research development disclosure invention patent foster development new improved therapy image touch yetscience innovation roche michael negrin israel year later tell story accord doctor suppose identify receive target therapy talking give year live specific mutation develop aggressive bladder cancer year later tell storyalmost result surprising doctor cancerfree living life mutation cause bladder cancer actually typical breast cancer patient year olda husband father grandfather joke bladder cancer patient year ago notice blood urine israel treat medicine breast cancer go doctor ask series patientsa combination target therapy test diagnose bladder cancer treatment condition improve markedly team doctor hospital decide month undergo surgery bladder remove plan change operation test specific diagnosis surgeon realise cancer spread offer detect early decide specific therapy doctor explain remove bladder instead substantial difference tumour chemotherapy locate site body sure test great benefit chemotherapy day week patient believe add alternate week challenge hook different healthcare system package tube process usually last cost cover underwent chemotherapy hour day chemotherapy go month damaging month change improve condition way prognosis tell doctor busy ready die oncologist tell year important test want lead normal active life new undergo comprehensive genomic test call granddaughter additional time foundationone explain test valuable help identify specific mutation worldaccess healthcare roche tackling challenge access healthcare mission ensure roche work healthcare system deliver rapid broad sustainable patient access novel product people wait hallway kenyatta national hospital nairobi kenyaone large medical institution east africa step globally hospital pharmacy abidjan cte divoire hospital cancer treatment place thank agreement roche sign cte divoire ministry health facilitate improve access innovative treatment hepatitis b c breast cancer roche passionate follow new department develop holistic access science area high unmet medical need bring strategy roche work healthcare system transformative medicine diagnostic test deliver rapid broad sustainable patient access patient realise product innovative medicine diagnostic want benefit patient actually reach bring product patient need access important topic fast possible sustainably healthcare system roche half world lack access essential health service million people push know extreme poverty health expense important roche engage stakeholder continue effort try change different healthcare system worldwide roche global scale develop systematic comprehensive approach working affiliate world september roche launch integrate effort identify barrier global access department preparation prevent patient benefit work internal external product step need take order stakeholder define roche access mission facilitate well access base analysis access strategy capability require develop partnership tailor solution country appropriate organisation need deliver bycountry situation theaccess healthcare roche material topic cover chapter sustainable healthcare pricing disease awareness treatment education growth strategy emerge market product think mean million people complete range offering patient support benefit treatment diagnose programme awareness campaign disease respective disease monitor access medicine foundation recognise effort follow patient journey strong accesstomedicine strategy area disease awareness diagnosis treatment general access medicine management roche funding sure people aware rank access medicine index disease educate support index analysis world large researchbased people receive proper early diagnosis pharmaceutical company prevent disease worsen patient product accessible low middleincome diagnose adequate healthcare capacity country place order deliver right treatment capability run infusion facility industry collaboration join force sufficient number train nurse doctor roche play lead role access accelerate difficult find country initiative launch crossindustry address treatment fund patient collaboration aim reduce barrier prevention protect excessive financial burden treatment care noncommunicable disease ncds low middleincome country address access barrier strategy end pharmaceutical company focus imperative access association involve programme affordability value recognition capacity outcome partner world bank group certainty follow strategy union international cancer control uicc able amplify access patient participate low middleincome country important cancer medicine herceptin initiative found member uiccs mabtherarituxan include city cancer challenge ccan support model list essential medicine effective sustainable cancer care delivery model represent increase population access select city key learning city kick close million challenge asuncin paraguay cali colombia kumasi ghana yangon myanmar year expand focus include participation provide insight perjeta new standard care combination international community local civil society herceptin woman herpositive breast public private sector well work cancer goal accelerate patient access city participate institution increase number patient treat healthcare professional patient herceptin plus perjeta emerge market connect transform approach local factor cancer care solution world health organization world bank group track universal health coverage global monitoring report roche commitment increase access patient platform p launch sustainable cancer care announce address challenge digital solution october act lead industry put patient centre enable affiliate partner work city develop region develop innovative efficient programme pilot model engagement ccan improve experience patient healthcare scale globally lead effort professional hcp alike support city globe spearhead design planning implementation stateofthe platform consist categoriespatient art solution cancer care far kigali rwanda onboarde treatment monitoring scheme porto alegre brazil tbilisi georgia management adverse event capturealong choose city phase ccan patient hcp portal solution allow patient control disease management digital platform support patient improve wellbee experience asiapacific region ambition ensure provide sense community connect patient access roche innovative patient hcp treatment patient support programme psp fundamental component access strategy p work reduce duplication region help realise goal psp process drive well insight analytic support launch process product date different psp afford opportunity use realworld asiapacific serve patient datum ensure compliance local law project show roche number malaysia country launch p hurdle region need resolve thailand taiwan follow later year instance common approach psp singapore australia follow asiapacific programme link longterm access strategy platform make health datum accessible available support well management analysis health datum potential help fight disease programme ensure fast patient access medicine drive future healthcareif accessible health system world collect different kind data genomic data realworld data clinical trial datum etc source infrastructure capture datum integrate leave datum disconnect incomplete patient asiapacific support psp unstructuredaccess healthcare roche datum drive healthcare healthcare datum access research healthcare information practice cphin leverage quality health datum drive prescribing access research decision canada connect datum important mission discussion early collaboration health delivering personalise healthcare canadian canada department canadian government personalize healthcare innovation network responsible national public health cphin initiative example start order positive partnership confirm build platform make health datum findable biopharmaceutical technology datum accessible establish collaboration management company recruitment roche canada canadian cancer trial partner ongoing group canadas genomics enterprise university health network university waterloo platform fund cphin partner initiative run notforprofit organisation leverage funding opportunity federal provincial government network cphin integrate datum platform provide design revenue model ensure search engine access realtime datum stream cphin integrate datum platform financially maintain patient privacy realtime selfsustaine long term access access datum insight platform foster agreement grant user canadian inform decision facet healthcare international private sector public sector turn accelerate innovation improve include researcher hospital institution payer efficiency low cost speed approval process government clinician able access improve patient care datum datum platform free charge continue fight hiv aid diagnosis improve country great progress year high disease burden collaboration tackle hiv pandemic number clinton health access initiative partner people die year aidsrelated illness provide accessible affordable pricing worldwide decrease steadily peak reagent consumable need hiv testing million million train healthcare worker roche offer support early diagnosis appropriate treatment programme help build healthcare system monitor possible people living capacity include participation publicprivate hiv normal healthy lifespan partnership ppps instance center disease control prevention area hit hard hiv vast invest develop country help region subsaharan africa access healthcare equip laboratory new technology centre diagnose treat follow hiv patient care extremely limited worldwide august formally launch partnership fourth person live hiv know kenya medical research institute status instal cobas hiv assay global access program partnership aim lead provider hiv viral load testing ensure people kenya access roche create global access program expand hivaid test viral load monitor access quality sustainable diagnostic testing ppp kenya initiative like roche scientific contributing unaid goal campus south africa demonstrate ongoing aim people live commitment africa capacity build hiv know disease status skill development supply diagnose hiv infection receive instrument sustainable pricing sustain antiretroviral therapy receive antiretroviral therapy number hiv test run viral suppression time high programme launch idea expand global start global access program access program area potentially access hiv viral load test early infant include additional disease area wwwunaidsorgenresourcesfactsheetaccess healthcare roche small blood person fingertip need cobas plasma separation card simplifie blood collection sample transportation remote area redefine reach reliable testing quantitative testing patient hiv live roche continue invest innovative product remote areaseven place experience solution expand access launch temperature c humidity sample cobas plasma separation card stable easy protect journey lab day touse sample collection device hiv plasma viral extreme condition load testing size credit card fundamentally change way sample take process sample send post viral load hiv testing test carry uptodate result care personalise adjust soon necessary traditionally viral load result require blood followup monitor people hivpositive sample cool transport lab achieve viral suppression help small blood fingertip stay healthy cobas plasma separation card allow reliableaccess healthcare roche merula steagall abrasta abrale brazil focus get proper understanding patient need live thalassaemia age sharing business good practice ngo year year live today group ngo country severe blood disorder work disease cancer impactful unite realise value network work private public effort lead work group influence decisionmaker bring colleague set movement change cancer bring institution private public sphere april contact mother work collaborative agenda aim boy thalassaemia know ask implement improve nationallevel policy help find information cancer prevention control disorder tell addition spur impact able set interest area patient advocacy observatory analyse monitor government brazilian thalassaemia society abrasta microdata cancer online education platform go curtail activity poor funding health professional physician lack interest parent offer establish develop research president new step revive begin project patient centre focus work ministry health year get proper understanding patient need able transform treatment situation listen patient primary brazil work expert help objective improve outcome change treatment outcome provide well access adequate treatment form abrale brazilian society patient group need work blood cancer widen impact political industry bring patient perspective decisionmaker physician design clinical trial early help worked treat blood cancer shorten process focus important expand formation thing patient care quality life red alianza latina network patient organisation survival want aggressive intervention latin america help upscale understandour people roche roche care people care people roche helps ensure patient well diagnosis therapy year young people begin vocational training roche basel kaiseraugst switzerland gathering insight future work life people purpose work design structure process principle govern operate encourage employee share insight improvement need history roche dedicate dedicated ensure roche remain deliver drive innovation help place creative gifted passionate people manage health breakthrough people desire work peoplethe collective medicine diagnostic solution unwavere source innovationare critical commitment stem unique highly factor success adaptable culture bring core belief purpose people value enable keep touch keep proactively evolve dramatically shift change business need landscape roche people understand power collaboration internally externally today world interconnect digitalise work effectively different geography increasingly complex new reality require time zone multiple project priority innovation flexibility speed stay align critical global demand ability challenge paradigm business recognise helping quickly recognise thoughtfully respond employee manager stay connected challenge opportunity roche dynamic fastpaced environment require transform way work sure different type dialogue cadence consistently meet need patient introduce checkin customer future new people practicesour people roche material topic chapter employee engagement talent retention compensationbenefit leadership commitment organisational effectiveness checkin conversation manager step uncover idea determine good employee focus employee solution aim consistentdevelope ideally happen facetoface conversation test new well fast way work schedule impromptu address ultimately help patient range important topic include contribution personal growth professional development pharmaceutical division provide good initiate employee example comprise global regional local manager checkin commercial structure setup need undergo discuss daytoday business focus individual substantial change efficient effective employee discussion tailor agile design sprint introduce identify need checkin launch address key challenge purposebuilt team organisation change employee manager assemble different department level communicate form essential organisation feature willingness people roche work embrace ambiguity challenge status quo increase agility drive manage change offer workplace see potential change business political environment roche welcome value visible require look individual invisible difference people age work different way gender sexual orientation culture thinking style agile organisation roche believe diversity inclusion essential define agility ideal balance speed generate innovationa culmination wide stability flexibility speed enable seize range opinion perspective create great opportunity arise analysis potentially transformative idea realworld data example flexibility help adjust approach suit new situation launch grouplevel campaign title stability provide clear important foundation personal campaign show personal employee strategic framework story submit employee high level leadership commitment code conduct commitment support diverse inclusive commitment sustainability example work environment focus individual emphasise dedication ensure roche work design structure work environment offer people needboth process principle govern operate office different area personal encourage employee share insight live need include different way working improvement need transparency flexible schedule unpaid leave option challenge opportunity critical need care sick relative diversity inclusion di overall mainly cause number structural change corporate goal fiveyear corporate goal organisation impact key position increase number woman key position increase number key position rocheability network example incumbent experience develop diverse inclusive workplace shape establish region achieve fiveyear group engage colleague support goal gender diversity key position sponsor initiative foster inclusion people incumbent diverse experience good disability team base basel kaiser progress year augst support employee see actual decrease compare caregiver partner family member global wellbeing week challenge participant reflect digital behaviourour people roche fiveyear goal increase representation woman key leadership role increase representation people establish develop region experience key leadership role quartile rank overall employee engagement score measure global employee opinion survey goal baseline disability bottomup effort reward connect learn prestigious roche pharma award roche believe expertise people locate function affiliate good basis people live work long decision oppose topdown approach multiple generation work innovation flourish diverse people connect offer opportunity benefit collaborate essentially create network perspective reverse mentoring widely utilise opportunity leverage people strength purposebuilt network platform utilise support learn participate colleague gain crossfunctional project good example valuable insight wide range area network support roche platform popular app simplify activity share provide suggestion start networkbased work experience connection project set meaningful way leverage exist expertise company strike right balance productively function project strive achieve balance group form particular business need common personal finding follow principle identify keep balance todays environment suitable team address need project run challenge global live initiative principle serve example start roche promote culture health wellbeing point fast development product employee address physical mental develop company view particular policy need people onsite exercise facility regulatory topic expert different area healthscreene programme medical counselling service legal financial advice resource workday new human resource system launch offering differ affiliate depend offer additional resource create local need opportunity internal network enable employee showcase professional expertise experience aspiration global wellbeing week focus specifically roche community availability digital wellbeing week site information empower recruiter project team introduce interested employee late trend individual search specific expertise find topic digital social wellbeing event right individual quickly easily end showcase new tool challenge participant month launch employee reflect digital behaviour start fill individual professional profile significant impact physical mental health workday visible wellbee interesting opportunity work roche offer variety opportunity time agile selfaware grow develop impactful development authentic understand change activity typically traditional classroom environment believe leader ship training necessarily directly link approach effective empower take new role region function offer people helping grow develop change perspective programme enable contribute employee experience different area role period month programme order accelerate transformation senior employee opportunity work project leader organisation participate develop leadership skill gain insight new kinesis programme introduce career path suitable kinesis aim help leader understand future programme help people think mindset behaviour directly impact career development decide effectiveness leadership programme want technical role start challenge leader confront pattern scientist software engineer think successful past people manager senior leader limit effectiveness introduce principle practice agile organisation roche believe everybody potential participant explore organisational transformation grow learn people level encourage learn requirement leader learn accomplishment challenges engage transformation journey day insight learning help boost entire organisation ability forward nurture attract talent time learning provide opportunity growth development opportunity grow improve utilise critical attract retain people good entire roche community valuable source leadership science technology core information experience business provide right development opportunity scientific technical talent leadership journey vital example scientific technical great leadership essential attract talent workstream engage multiple retain people talent dedication department function focus leadership commitment introduce remain specific theme interaction important foundation leadership culture function human resource department foster understand people need evolve environment continually grow thrive include way fully leverage present new challenge opportunity recognise scientific contribution expectation place leader fundamentally change past decade today leader need digitalisation deeply embed demonstrate new capability embrace leader roche codelife initiative effort raise ship style mindset focus people roche profile digital talent notour people roche technology challenge c personalise healthcare c lab automation java haematology python diagnostic mongodb cancer immunotherapy html drug discovery docker clincal trial spring outcome prediction asw oncology r safety report process jupyter notebook javascript sql linux nodejs tibico angularjs jenkin user interaction technical talent codelife initiative cover technology challenge codelife initiative aim showcase technology drive innovation healthcare example highlight technology help solve challenge diagnosis aware extent digitalisation country switzerland germany codelife change world diagnosis treatment roche site basel kaiseraugst codeliferochecom option patient codelife competition example teach methodology open university team individual content meet high standard apprentice external roche process gain valuable experience profession include participant learn significant impact informatic biology chemistry automation healthcare digital capability electronic area closely couple translate directly benefit people research manufacturing programming need urgently codelife initiative printing robotic pro interaction online campaign gramme provide insight development drive visit view manufacture medicine apprentice website recognise code capability participate exchange site exist unconventional place mannheim penzberg germany company launch initiative identify digital talent organisation talente people world collectively engage solve challenge problem believe valuesintegrity courage passion purposedoe patient need progress digitalisation roche make meaningful difference reflect vocational training offer day help ensure roche continue apprenticeship system establish innovate benefit patientsour people roche jutta steinseifer roche switzerland need well understand patient consider benefit year ago go doctor patient patient realise routine mammography screening offer important involve patient woman germany receive partner drug development information diagnosis gift prior need well understand patient consider christmas house guest benefit acceptable term journey look breast cancer toxicity treatment going receive rebel life new mindset approach physician course need involve treatment work medical director expertise advise patient herceptin breast cancer medicine treatment option need develop help million woman world fill product focus patient need learn hope provide scientific personal cancer journey doctor argument need challenge status quo know matter patient need involve patient directly thing learn journey seat table difficult discussion doctor easy bring second pair ear attach addition work external patient function brain brain overwhelmed group tap knowledge information year later work roche colleague thank support wife daughter patient live patient work friend roche help need way real advice achieve roche patient network huge asset group join return treatmentpatientsareus word advice use mammography screen available city town roche right track making family member friend great effort patient centre work afraid ask question second well example opinion satisfy oncology room improvement recommendation trial patientfriendlierenvironment roche minimising impact environment roche protect environment legal social obligation integral operation sustainability priority construction project like site kaiseraugst switzerland proactively seek new technology regularly inspect pharmaceutical diagnostic manufacturing facility environmental performance implementation environmental policy environmental protection central long good environment roche reputation term priority everchange world roche corporate audit team inspect pharma protect environment integral ceutical diagnostic manufacturing facility operation take seriously environmental performance implementation life cycle product corporate principle environmental policy keep legal safety security health environmental requirement internal standard protection policy ensure commit recommendation future improvement high standard environmental protection commit continuously invest chf million environmental monitoring key performance indicator eg infrastructure chf million environmental year goal aim cover operating cost include service personnel key performance indicator environmental management compliance believe education awareness training roche environmental risk mitigate good way foster employee engagement multid isciplinary system prevention responsibility mind successful environmental management system ems conduct regular training session regional proactive system reduce cost increase conference workshop provide online environment efficiency enhances competitiveness dedicated tool local language employee rochecom team employee globe identify potential employee participate approximately environment risk possibly cause damage people hour dedicated trainingenvironment roche material topic chapter environmental responsibility noise pollution emission water primary energy emission air roche ecobalance landfille waste water consumption minimise environmental footprint fiveyear goal measure total environmental impact ecobalance metric system ecobalance point allocate ecologically relevant parameter million pointsemployee metric provide global view impact earth ecosystem allow local site management freedom develop energy consumption locally appropriate strategy objective gj ffeemployee reduce environmental impact point add relate total number employee enable monitor general waste environmental impact employee strategic kgemployee goal reduce ecobalance th e n wn ed h v e b w eee n r ae ia mch ine gd tt oh rs e dgo ua cl e u r f pi rn ince water consumption year improvement term memployee decrease energy consumption air emission water consumption weight chemical goal waste lead improvement compare ffe fossil fuel equivalent weight water stress change relate respectively develop swiss federal office environment compliant late guideline decrease energy consumption energy management programme twofold success reduce energy consumption seek improve energy efficiency carbon dioxide emission credit global operation turn reduce initiative like renovation chimney environmental impact strain basel site result significant increase energy supply chain cost secondly energy efficiency approximately endeavour reduce usage fossil fuel cut energy result avoidance consumption increase proportion sustainable tonne co year monetary term energy set energysave action plan mean roche save approximately site include implementation chf year fuel cost innovative technology continuous upgrading infrastructure improve energy efficiency reduce emission hybrid car roche diagnostic indianapoli total energy consumption decrease convert car fleet hybrid sale grow energy building car new strategy help reduce stationary equipment gas fuel oil waste electricity energy fleet vehicle district heating comparable approximately energy compare energy business air travel decrease term carbon dioxide emission approximately contribute move hybrid car reduce emission fifth roche total energy consumption approximately energy consumption terajoule share sustainable energy total scope scope energy energy scope rochecom consumption gj environment employee resourcesand scope goal rawmaterial business flight sustainable nonsustainable scope energy generate facility eg combustion gas scope purchase energy datum collect group gj gigajouleenvironment roche energy use select type energy business air travel video teleconferencing facility establish site widely employee encourage use train consolidate business trip grid electricity priority reduce usage energy energy use look way improve efficiency heat recovery addition encourage use renewable energy make sense natural gas energy company vehicle stipulate company car fleet consist vehicle use mjkm sustainable construction san francisco campus wellness building occupant genentech genentech long incorporate sustainability achieve lee platinum certification principle plan development new building campus complete south san francisco ssf campus adopt building represent first holistic approach encompass green building genentech include net zeroenergy performance design employee health wellbee annual energy generate building genentech reduce greenhouse gas solar photovoltaic system solar hot water panel emission energy ssf campus equivalent energy thank green building programme building year additionally lifecycle assessment achieve lee gold certification complete project design demonstrate campus community center genentech pursue environmental benefit building wood build certification firstofitskind construction include save embody standard emphasise health productivity carbon compare steel structure reduce greenhouse gas emission greenhouse gas ghg emissionssuch emission air roche site carbon dioxideresulte human activity low level consider responsible accelerate global warming climate change industry source emission air tonne emission appropriate measure reduce impact international agreement paris agreement roche actively support voc national legislation define target particulate schedule reduce emission work nitrogen oxide goalset reduce sulphur dioxide scope ghg emission employee volatile organic compound year emission strategy prescribe continuous initiative reduce ghg emission roche improvement manufacturing site reduce use halogenate refrigerant aim avoid reduce control air pollutant cool equipment remain line ecobalance goal despite increase atmosphere long period time production result continued growth commit reduction use objective emission air halogen compare penzberg low level achieve past year germany work local supplier develop new technology natural refrigerant able reduce scope ghg emission date able replace kg implement energysaving measure halogenate substance avoid ton reduce fuel use heat cool carbon dioxide equivalent approach apply operate site ghg emission originate environmentally friendly refrigeration honour transformation purchase energy consume regional government scope reduce halogenate hydrocarbon tonne emission total project rochecom complete result avoidance approximately environment tonne co emission lead inventory emissionstoair estimate costsave approximately consume release andtowater chf million global inventory include chugai genentech ventanaenvironment roche tonne co emission avoid long term goal fully substitute fossil nuclear energy energy renewable source diagnostic site suzhou china instal photovoltaic panel cover energy need administration building co equivalent emission tonne scope fuel combustion halogenate hydrocarbon scope marketbase locationbased total scope marketbase scope business flight energyintensive utility waste change report methodology number different report compress air liquid nitrogen reduce water consumption waste currently roche highusage operation efficiency meet ecology area water scarcity waterrelate risk aim implement follow waste manage adapt conservation reduction ment strategy waste activity avoid reduce programme accord local condition need reuse recycle thermally destroy permit californian site example use drought landfilling resort resistant landscaping site collect inert material slag ashe waste recycle water cool tower create minimisation reduction measure closedloop system reduce water use reduce restrict production process evaluate total water consumption important implement operation roche overall environmental target water goal strive ecoefficient solution reflect reduction environmental burden economic benefit eg reduction raw material water usage discharge disposal cost landfille incinerate waste tonne water withdraw million water consume general waste million generate water discharge chemical waste treatment plant generate million contaminate soil organic matter construction waste discharge waterway prior datum collect separately treatment heavy metal discharge roche innovation center copenhagen waterway denmark press sell waste recycling treatment kg company monetary compensation toenvironment roche tonne co emission avoid year reagent production transportation cover waste press recycling waste avoid address customer demand greener product carbon dioxide emission link incineration supply chain public concern chemical procedure kg cardboard pharmaceuticals environment kg paper press sell avoid approximately kg carbon dioxide pharmaceutical environment initiative benefit environment trace pharmaceutical product enter company environment variety way include manufacturing process improper disposal unused develop new diagnostic system reduce medicine natural metabolic process impact environment crucial element follow normal patient use roche acting process innovative instrument design concern impact pharmaceutical vast experience test development allow environment consider entire life cycle operate low reagent volume product mabtherarituxan herceptin produce small reagent carrier generate avastin perjeta lucentis monoclonal waste test implementation cobas e antibody generate chf billion pack green cobas c pack green avoid sale belong define class active tonne co emission pharmaceutical ingredient apis exempt year reagent production transportation european medicine evaluation agency guideline represent flight basel san environmental risk assessment francisco ecological mindset help customer low excretion rate deem present product address key challenge lab test significant risk sewage work surface water stewardship sustainability effort reflect commitment term benign nature rochecom product stewardship roche aim minimise constitute environmentally sustainable compound environment safety security health environmental impact pharmaceutical product product product device effort help subject rigorous environmental risk assessment stewardshipcommunity engagement roche strive longterm community engagement work bring change well variety form mobilise resource serve catalyst strengthen sustain local community fund raise annual roche children walk initiative support education health social development world roche ambassador chance visit selam children village ethiopia experience firsthand progress resource good use path strong society mother live roche children centre mumbai learn embroidery skillbase workshop conduct centre help parent acquire new skill generate increase income family strengthen community reason employee worldwide operate roche responsibility global join force annual roche children citizen philanthropic engagement direct walk raise money local project support humanitarian social project employee country participate foster science education art culture effort matching contribution provide longterm disaster relief support roche chf million collect project run international ngo year support children project headquarter local project manage affiliate collaboration local ngo provide holistic care child cancer know need country well project fund children walk partnership st jude india childcare make meaningful difference take time centre organisation provide shelter happen partnership give time care child undergo cancer therapy opportunity evolve approach country like india provide access medicine honour achieve excellent score take effort make medicine corporate citizenship philanthropy available commercially need dow jones sustainability indices recognition create environment patient able important crucial project thrive start complete treatment resource good usecommunity engagement roche material topic chapter community engagement sustainable healthcare disease awareness treatment education therapy paediatric cancer subsidise travel state maharashtra teach basic free charge tata occupational skill parent st jude india centre memorial hospital mumbai dropout rate state significant simple reason third patient come outside mumbai connect local healthcare system housing city mean partnership st jude india roof head weaken disease way roche alliance history effect chemotherapy child prone begin journey year ago infection find difficult fight cancer healthcare train phelophepa successful humanitarian project south africa roche open centre mumbai roche health clinic pharmacy clinic campus st jude india offer clean safe place board deliver primary healthcare health stay child cancer give time education impoverished community remote family feel home area phelophepa train run week year duration treatment nutritional support travel remote community annually education counselling apart roche inception phelophepa train take financial contribution employee volunteer time place year ago today train run passion arrange recreational activity like provide treatment million patient perform dance storytelling session dispense prescription partnership help decrease overall dropout rate treatment paediatric cancer mumbai child find temporary home away home overall dropout rate treatment roche centre complete treatment paediatric cancer mumbai decrease watch project flourish expand partnership st jude india open second centre eastern region assam roche establish mobile training van unlocking potential grow talent education break vicious cycle poverty foundation renovation work well teach child skill knowledge need employment condition local worker develop improve life roche philanthropic engagement accompany addition promote school readiness educational component programme launch unicef ethiopia initiative support roche carefully choose local partner ensure recognise ethiopian ministry share value integrity fairness accountability education childtochild project improve transparency employee school readiness peer tutoring old children walk fundraiser child help roche child opportunity visit partnersthe selam access early learn opportunity children village ethiopia witness initiative progress fund corner world foster education close home selam nonprofit organisation provide numerous project design promote interest housing holistic care orphan child science technology young people ethiopia develop self roche found sponsor reliant selam quality school run age international swiss talent forum think tank technical vocational training centre young adult world address benefit disadvantaged child youth global longterm challenge time surround community connect student expert decisionmaker lateral thinker international swiss talent roche support total child forum create space innovation interaction live orphan home run house mother debate develop new solution globally addis ababa city yeka sub city kotebe wereda significant issue young adult age bole sub city youth vocational training year country world selam school training centre objective come find novel answer challenge allow student focus entirely face future urban life education remove financial pressure city handle fastgrowe population hinder progress student city selfsufficient year complete train far able student chance reflect artificial find job quickly additional funding help intelligencecommunity engagement roche diligence legal framework high school student involve fouryear coursework futurelab school year futurelab genentech initiative develop genentech provide monthly support benefit accrue cooperation south san francisco unify side volunteer programme school district design inspire k student like science garage likely stay kindergarten th grade exploration genentech report develop skill career science technology engineering result volunteer mathematic stem sharing skill experience science garage new futurelab roche ongoing commitment offer fouryear biotech pathway design improve education develop country high school student chance discover exciting microsecondment combine knowhow field biotechnology science garage start skill roche employee local ngo build threeweek biotech unit ninth grader capacity deliver sustainable output increase compulsory biology course impact umbrella collaboration school year student run experiment field b education partnership facilitate classical genetic gene identification knowledgeshare europe africa roche employee serve guest lecturer appetite biotechnology namibia university science demonstrate student technology nust windhoek roche partner continue pathway additional elective university run programme biotech coursework course year environmental health science support student familiar variety coaching student handson exercise concept laboratory technique career pathway teach logistic supply chain management biotech industry year student student assignments south san francisco school district conduct close colla boration university involve fouryear programme integrate real business case curriculum encourage employability support durable apart teacher deliver unit knowledge transfer course employee volunteer fromintegrity business roche continue commitment integrity business apply high ethical standard activity foundation success integrity pay stakeholder society large business overall work closely supplier construction engineering ensure sustainability business matter culture aim translate formal guideline businessintegrate compliance create positive impact business practice expectation clear patient healthcare shed light grey area professional authority society large comprehensive compliance management trust act ethically responsibly effort facilitate businessintegrate impact bind law reputational orient decision simplify process reason live value adhere principle trust verify mean employee leave work integrity professional virtue ask count supportive connect employee expect assess risk compliance officer network unethical behaviour area accountability prevent mitigate adopt face organisation role model corrective measure roche philosophy serve employee general manager gms play central approach start point culture integrity role foster ethical behaviour respective rochecom embed everyday business result team mind compliance induction approach compliant behaviour programme new gms launch recentintegrity business roche material topic cover chapter compliance occupational accident drug efficacy safety counterfeit datum transparency clinical trial patient organisation support supply chain management year tailor affiliate need help colleague tool develop discuss compliance topic help practical provide approval workflow repository example overall objective sure document compliantly manage interaction gm able foster culture employee healthcare professional hcp tool assist accountable right thing carry diagnostic affiliate panama interaction responsibility hcp central america caribbean country concept evaluate example embed compliance diagnostic diabete care affiliate business compliance maturity questionnaire stem creative idea pharma originally develop france tool help ceutical organisation compliance app compliance officer management understand available pharmaceutical diagnostic compliance status identify area advancement diabetes care team latin america discuss compliance different click button sale staff retrieve information business team wide organisation compliance key compliance criterion requirement business partner different department judge app tool analyse reference different topic plan compliance programme campaign example speakup culture communication management case noncompliance adapt affiliate questionnaire serve valuable tool local compliance management identify compliance risk set priority accordingly compliance employee roche group speakup line pioneer integration digital tool available language countrie chief way simplify access relevant information compliance officer receive report relate alleged compliance continuously enhance violation code conduct business ethic integration digital tool instance latin incident reporting system unfounded america challenge highly heterogeneous found investigation region term legislation country size result employment contract agreement market characteristic meet innovative business partner terminate ground unethical solution assist medical decision service behaviour ensure operational resilience keep ongoing effort sustainable consequently track achieve development roche strive continuous midterm target period improvement area safety health security year implement health wellbee employee roche variety initiative improve excellent business partner organisation track record area accident health priority consequently business partner expect meet rigorous standard result number accident constant policy bearing fruit establishment low graph vast majority slip new diagnostic site suzhou china trip household accident rate worker spend seven million work hour low single accident result long absence reportable accident lead fluctuation accident rate key figure set feasible ambitious goal responsible prescient handling chemical establish health safety committee roche june roche comply mandatory production site site accord requirement european union regulation risk level registration evaluation authorisation restriction chemical reach register employee health safety exist substance volume tonne year chemical roche traditionally go legal requirement instance initiate pilot project european chemicals agency echa partner company share archived datum scientific community improve knowledge toxicity chemical substance help reduce number animal study initiative involve substance high concern svhc list goal echa set ambitious goal losttime illness rate roche accident rate voluntarily phase svhc losttime accident rate number workrelate accident product process worldwide year working day lose year accident appear list technically feasible threeyear averageintegrity business roche protect harm tamper digitalisation integral approach security digital solution apply area product travel security example travel tracker system facilitate ontrip support rapid identification traveller case emergency enable roche security team contact colleague travel inbuilt email sms handle emergency event support people worldwide counterfeit pharmaceutical devoid active ingredient contain harmful substance state incorrect dosage inappropriately package label masquerade medicine employ anticounterfeit strategy combat counterfeiting help ensure patient risk treatment failure dangerous quality product effect todays global trade system open possibility introduce counterfeit product regular supply chain coordinate counter effort collaborate international criminal effort combine great awareness anticounterfeite investigation authority strict legislation help ensure rochecomanti safe supply critical medicine patient need counterfeit roche genentech chugai members pharmaceutical security institute host database product crime case comparison datum provide opportunity business continuity management identify specific logistic company distributor september hurricane maria leave trail death notify law enforcement destruction puerto rico island home roche authority roche close suspect manufacturing site glucose test strip area case confirm diabete care storm impact employee local affiliate roche site hit power outage damage use internal analytical skill examine overall infrastructure substantial challenge aftermath sample counterfeit identify storm connectivity especially access roche composition medicine impuritie network employee work hard impact contamination scientist analyse ink packaging disruption minimum preventing shortage product leaflet blister paper investigate counter diabetes patient worldwide possible process feit detect different location world place focus improve resilience network find originated source today puerto rico affiliate operation partnership last future view improve sustainable patient stakeholder rwd partnership patient roche update directive roche access use rwd undertaking collaborate patient group patient activity aim ensure datum protection guideline acknowledge role play allow use datum drive medical innovation increasingly empower vocal patient population directive patient define sustainability supply human right broadly include patient organisation patient united nations guide principle business group patient associ ations patient advocacy group human right embed operation patient community patient expert online patient multiple mean assess risk community family member caregiver potential violation promote awareness foster individual patient diligence strengthen legal framework collaborate collective action transparent interact patient able gain communication great understanding need patient perspective guide clinical development conduct human right risk assessment example define meaningful clinical trial endpoint crossfunctional representative reflect newly launch patient support corporate sustainability committee platform forpatient provide disease education identify human right potentially information roche clinical trial susceptible violation associate layperson language provide relevant risk enhance awareness create video information make easy caregiver explain human right roche endeavour patient connect possible clinical trial site simple message employee sphere influence ensure human right respect respect privacy datum protection patient believe access use realworld datum carry riskassessment approximately rochecom rwd legitimate purpose benefit patient business critical supplier broaden patientorganisation provide appropriate safeguard place supplier diligence expand interaction patient stake collaboration businesscritical supplier forpatient holder need respect privacy year systematically identify riskassess critical tier forpatientsrochecom adjust policy framework datum privacy light supplier specifically look country new european union general data protection industry know high risk violation position rwd regulation gdpr take opportunity human right total find high rochecomrwd evaluate current practice develop roadmap risk tier supplier logistic ensure requirement gdpr meet company nigeria thailand temporary human right addition involvement stakeholder labour company mexico verify rochecomapproach roche elaborate position paper access tier supplier mitigation plan place humanright use rwd explain tremendous value suppliersintegrity business roche human right approach benchmark increase awareness enhance legal framework transparent communication assess risk foster diligence collaborate collective action continue supplier sustainability baselbase brgerspital provide assurance visit support external audit important service roche introduce firm complete visit area inclusive internship programme local organisation labour condition finding want improve diversity workforce include excessive overtime improper pay internship open people vary overtime insufficient number rest day disability range physical disability inadequate payment social benefit work neurodevelopmental condition supplier address finding example sustainability assurance visit chinese supplier pharmaceutical manufacturing equipment reveal unsatisfactory standard working condition especially regard health engage public policy stakeholder public policy safety environment worker convince responsible constructive form rochecom excessive overtime receive insufficient lobbying interest party involve society approach training addition company carry seek inform work closely government publicpolicy regular fire drill supplier successfully official order highlight address issue affect implement corrective action healthcare industry advance regulatory framework update good practice guideline work focus ability government official appropriate roche disclose recognition human right ensure contribution sign transparency register public people right treat dignity authority switzerland spend chf million rocheability network instance foster include payment industry association inclusion basel kaiseraugst employee chambers commerce financial assistance trade union disability focus strength ability donation political party cantonal federal level individual basel kaiseraugst site donation political party low doubledigit start work inclusive provider thousand range swiss franc account plan expand collaboration example approximately total contribution donation safety security health environment image touch yetintegrity business roche dr nicole gusset sma switzerland red line patient organisation cross daughter victoria diagnose spinal grant help understand muscular atrophy sma year birth input relevant transparent communication caregiver child sma need share confidential information patient everythingtime space money energy emotion organisation need order sma affect aspect life merciless meaningful contribution red line killer constantly try grab child patient organisation cross interest try stay ahead patient wellbee reach centre decision action compromise soon devastating diagnosis start effort contribute development healthcare industry undergo change therapeutic sure meet increase digitalisation access datum patient need need knowledge partner well inform demand patient battle found patient organisation sma safeguard protect individual switzerland join force sma europe aware potential consequence family give great support victoria inform decision like think personal data constant motivator driving force help belong individual incredible raise patient voice pursue inclusion opportunity lie ahead apply big data discussion decisionmake drug surely fusion discovery big human development datum technological advancement fundamentally change face medicine sma switzerland work closely stakeholder drug development process patient input star treklike scenario patient scan essential level cooperation medical tricorder identify health status pharmaceutical company currently provide rescanne treatment long expertise work group advisory board science fiction personally sma near protocol design trial operation communication future foresee combination different therapy tailor patient personal need pair partnership work goal graceful robotic device replace clumsy clearly formulate insight internal process wheelchairs mechanical aid todaycorporate governance roche corporate governance principle focus business activity sustainable value creation innovation prescribe management culture conforming recognise standard good corporate governance policy transparent communication roche continously modernise infrastructure ensure successful sustainable operation principle roche corporate governance principle focus roche complie relevant business activity sustainable value creation corporate governance requirement particular innovation prescribe management culture applicable law swiss stock exchange conform recognise standard good corporate swiss exchange directive swiss code governance policy transparent communication good practice corporate governance promulgate principle build basis successful swiss business federation economiesuisse implementation roche commitment serve company internal governance framework stakeholder particularly article incorporation bylaw embody principle need ensure strong board director represent company business manage supervised interest shareholder stakeholder manner consistent good corporate governance highly skilled manager act integrity include necessary check balance extremely important print annual report contain select link th consecutive year roche roche website wwwrochecom reader recognise sustainable company provide snapshot pharmaceutical index dow jones sustainability company report date direct index djsi base indepth analysis source consult time economic social environmental performance uptodate information corporate governance djsi serve benchmark investor integrate roche annual report cover single sustainability consideration portfolio financial year end december website sustainability core business practice contain information permanent nature award reflect commitment run late roche news company article business way ethical responsible incorporation bylaw curricula vitae create longterm value stakeholder current member board director corporate executive committee publish corporate governance report set website structure process rule roche take basis wellfunctione corporate governance detail refer follow report annual general meeting annual general meeting board director board director board committees board committee presidium nomination committee remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee ceo ceo ceo cfo hr general roche group pharmaceutical diagnostic counsel enlarge corporate enlarge corporate executive committee executive committee gre pre partnering communication rochecomgovernancecorporate governance roche board director th annual general meeting agm addition agm elect dr christoph franz roche holding ltd march shareholders andr hoffmann prof dr richard p lifton reelect dr christoph franz chairman bernard poussot peter r voser member board director remuneration committee furthermore agm reelect andr hoffmann organising meeting immediately follow prof sir john bell julie brown paul bulcke anita agm board director determine hauser prof dr richard p lifton dr andreas oeri structure composition remain bernard poussot dr severin schwan dr claudia committee show page suessmuth dyckerhoff peter r voser term board director corporate year provide article incorporation executive committee board director board director board committees board committee presidium nomination committee remuneration committee audit committee corporate governance sustainability committee composition year birth elect board director dr christoph franz c e chairman andr hoffmann representative c e vicechairman shareholder group pool voting right dr andreas oeri representative e shareholder group pool voting right prof sir john bell b e julie brown b e paul bulcke b e anita hauser e prof dr richard p lifton c e bernard poussot c e dr severin schwan f dr claudia suessmuth dyckerhoff b e peter r voser c e secretary dr gottlieb keller board director honorary chairman dr fritz gerber board director corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson march forthcoming agm july roche announce dr andreas board director nominate chairman oeri informed board director remain member board director stand reelection member reelection board director annual general meeting conclude year term office addition board director propose prof dr jrg duschmal fifthgeneration descendant dr hans clevers professor molecular genetic founder roche confirm interest university medical center utrecht netherlands standing election member board election board director director agm previous year board director board director nominate nominates bdo ag independent proxy dr christoph franz andr hoffmann prof dr period conclusion richard p lifton bernard poussot peter r voser ordinary annual general meeting shareholder reelection member remuneration election agm committee agm corporate executive committee daniel oday ceo roche pharmaceutical roland diggelmann ceo roche diagnostic member corporate executive committee member corporate executive committee leave step role december roche pursue career outside company end february prior assume effective september successor new responsibility outside roche provide name dr michael heuer head region support ensure smooth transition activity europe middle east africa latin america roche diagnostic assume ad interim william bill anderson ceo genentech leadership roche diagnostic division appoint ceo roche pharmaceutical effective member corporate executive january new member corporate committee executive committee report dr severin schwan ceo roche group corporate executive corporate executive committee committee ceo ceo ceo cfo hr general roche group pharmaceutical diagnostic counsel enlarge corporate enlarge corporate executive committee executive committee gre pre partnering communicationscorporate governance roche composition year birth position corporate executive dr severin schwan ceo roche group committee daniel oday ceo roche pharmaceutical dr michael heuer ceo roche diagnostic dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarge corporate dr michael varney head genentech research executive committee early development gre dr william pao head roche pharma research early development pre dr james h sabry global head pharma partner dr stephan feldhaus head group communication secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey mark baillache business year chief compliance officer dr urs jaisli prof john c reed head roche pharma research head genentech partnering appoint early development pre leave roche personal global head pharma partner new reason april order return united member enlarge corporate executive state effective april william pao committee new role combine genentech global head oncology discovery pharma partnering function furthermore translational area pre appoint osamu nagayama retire enlarge successor member enlarge corporate executive committee join corporate executive committee effective july dr sophie kornowskibonnet information member corporate head roche partnering member enlarge executive committee enlarge corporate corporate executive committee leave company executive committee list page pursue career outside roche effective board director corporate august dr james h sabry global executive committee group structure shareholder roche operate business organise integrate roche pharmaceutical diagnostic division pharmaceutical diagnostic division consist follow business area pharmaceutical division comprise business centralise point care solution molecular segment roche pharmaceutical chugai diagnostic tissue diagnostic diabete care genentech segment pharmaceutical roche pharmaceutical incl genentech chugai centralise point care solution diagnostic molecular diagnostic tissue diagnostic composition diabete care dr andreas oeri chairman corporate governance sustainability committee andr hoffmann chairman remuneration committeecorporate governance roche business activity carry group andr hoffmann vicechairman board exchange subsidiary associate company detailed director chairman remuneration regulation information roche holding ltd significant committee dr andreas oeri member sixexchange subsidiary associate company include board director chairman board regulationcom company list information domicile share corporate governance sustainability committee enhome capital equity interest list finance report serve respective capacity board publication note roche group consolidated financial committee representative shareholder significant statement list subsidiary associate group pool voting right receive shareholder remuneration set forth remuneration report major shareholder list finance report finance report note note roche group consolidated roche group consolidate financial statement financial statement equity attributable roche relate party exception shareholder relate party page dr jrg duschmal work postdoc note financial statement roche roche end september holding ltd significant shareholder relationship exist shareholder pool addition significant shareholder publish voting right relevant webpage disclosure office exchange regulation crossshareholding capital structure information roche capital structure provide protect interest ne holder describe finance report note financial statement article incorporation roche hold ltd roche holding ltd additional detail contain article incorporation roche information debt instrument hold ltd issue outstanding bond provide finance report note roche group movement recognise amount consolidated financial statement debt financial year detailed finance report note financial statement roche holding ltd information employee stock option provide finance report note roche group consolidate financial statement equity company share capital chf compensation plan include detailed divide fully pay bearer share information stocksettle stock appreciation nominal value chf restriction right ssar plan restrict stock unit exercise voting right share rsus plan performance share plan psp deposit share vote restriction roche connect roche option plan authorise conditional capital roche issue option apart employee stock option describe finance report note addition nonvoting equity security roche group consolidate financial statement ne issue bearer form form equity compensation plan option share capital confer voting right issue connection debt instrument ne confer right share participate available earning liquidation proceed option award employee debt follow repayment share capital roche ne instrument issue effect right pertain thereto include provision roche share capital rochecomarticleofincorporation board director corporate executive committee information member board period lack exist business director member corporate connection group subsidiary independent executive committee list page roche board director independence definition member board director age limit base definition swiss code good restriction term office curriculum vitae practice corporate governance economiesuisse current member complement specific precede criterion year body information rochecomboardofdirector include information year election additional position membership principle governance principle activity available continuously update delegation competence reservation power internet management group company executive body company include economic rule pursuant article para point vegv environmental social topic principle number permit activity board internal organisation director corporate executive committee board director division authority member outline article responsibility board management incorporation roche holding ltd remits board committee information control mechanism available annual general meeting elect board dealing corporate management member board director chairman govern bylaw board director member remuneration committee annual basis board director roche holding ltd election nominee vote separately organise ensure group conduct article incorporation roche business responsibly focus hold ltd minute th annual longterm value creation end roche board general meeting roche holding ltd hold delegate certain responsibility march committee composition chairperson december describe exception dr severin schwan committee authority responsibilitie member board director office define detail bylaw board end member roches corporate director executive committee serve executive capacity group subsidiary committee chair independent financial year preceede current reporting director rochecomboardofdirector rochecomexecutivecommittee rochecomarticleofincorporation rochecomannualgeneralmeeting rochecomarticleofincorporation rochecomcommittee rochecomarticleofincorporationcorporate governance roche board director board committees board director presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee accord bylaw board director pharmaceutical diagnostic division board meeting convene chairman global function conduct formal risk assessment present request member roche process year develop risk plan board meet year assess chairman material risk monitor performance meeting attend deviation review regular performance dialogue chairman chair vicechairman consolidated group risk report include target risk profile discuss corporate executive management information system committee approve group mis board director regularly inform business plan material risk review important issue sale performance board yearly basis effectiveness risk etc board access electronic information management process monitor group risk platform provide timely information advisory team overall process regularly board director board committee review external auditor finding present system control set forth audit committee board detail risk management include risk factor board director establish system risk management policy risk management control continuously monitor website financial risk management specifically audit committee corporate governance describe finance report sustainability committee board system internal control financial reporting director consist follow element page finance report report operate financial risk risk internal audit management system group audit report general counsel roche group establish risk management direct access give regular briefing audit process cover entire company system committee corporate governance place identify manage type risk sustainability committee ongoing activity potentially affect business include economic audit report chief audit risk advisory environmental social impact risk executive attend audit committee partly opportunitie contain stakeholder input corporate governance sustainability committee board director high governance meeting external auditor group audit body involve roche risk management policy set independent appraisal function evaluates approach accompany responsibility review group activity service rochecomriskmanagement additional information provide finance report note roche group consolidate financial statement risk management management annual audit plan yearly trading company stock follow blackout define focus area eg market access thirdparty period effect management validate senior management december january present audit committee roche april april group commit maintain high standard june july internal control worldwide october october operation management responsible assess business risk aspect operation blackout period change chairman implement effective efficient process board director circumstance warrant control whilst ensure compliance internal external rule regulation board director meet meeting conduct operational audits group audit generally hour length include determine management response risk fullday meeting addition day visit surround business process system major subsidiary evaluate appropriateness completeness efficiency process control action plan board committee meet follows implement necessary change enhancement presidium board directorsnomination develop businessauditee committee meeting approx hour track completion remuneration committee meeting approx statutory auditor hour chief compliance officer compliance officer audit committee meeting approx hour subsidiary safety health environmental protection corporate governance sustainability department committee meeting approx hour corporate sustainability committee science ethic advisory group seag board director regularly conduct issue relate genetic genetic engineering assessment selfassessmentassessment party electronical survey personal member corporate executive committee interview performance invite attend meeting board director party evaluation conduct report person agenda item concern situation warrant member corporate executive committee member enlarge corporate executive maximum ordinary notice period committee invite attend board month changeofcontrol clause committee invite chairman board employment contract corporate executive committee member deliver report committee meeting elect management contract fall commission independent expert report scope subsection annex service consultant directive information relate corporate governance year blackout period impose senior employee prohibit rochecomenvironment rochecomsustainability rochecomethicalconflict remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activitiescorporate governance roche dr andreas oeri chairman corporate governance sustainability committee attendance board board committee meeting corporate presidium governance nomination remuneration audit sustainability board committee committee committee committee number meetings ch franz hoffmann j bell j brown p bulcke hauser rp lifton oeri b poussot schwan c suessmuth dyckerhoff p r voser member committee remuneration shareholding loan rule aol detail remuneration shareholding loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional payment page finance report note member executive roche group consolidated financial committee appoint statement equity attributable roche shareholder vote pay general relate party page list meeting shareholder note financial statement roche holding rule loan credit facilities ltd board executive shareholding postemployment benefit rule vote pay follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi participatory right shareholder participatory right shareholder define article incorporation roche article incorporation roche shareholder represent share nominal value share issue bearer restriction chf million request placement admission annual general meeting item agenda annual general meeting exception share deposit later day specify period date meeting date meeting admittance card issue shareholder provide article rule issue instruction incorporation shareholder elect independent proxy rule electronic represent party annual general participation agm lay meeting correspond invitation agm regulate article incorporation article incorporation contain restriction exercise voting right quorum requirement stipulate conformity swiss code obligation rochecomarticleofincorporationcorporate governance roche change control defensive measure article incorporation contain provision terminate event acquisition mandatory bid rule swiss law apply vest period restriction preexist award remove option changeofcontrol clause exercise immediately component remuneration base roche ne relationship statutory auditor annual general meeting roche holding ltd march shareholder vote appoint millions chf kpmg ag kpmg statutory auditor audit service auditrelate service base exist legal requirement swiss assurance code obligation article concern nonstatutory audit maximum term office seven year auditor tax service charge ian starkey auditorincharge service business year replace mark baillache total start business year information long auditor auditorincharge statutory auditor elect year serve capacity provide annual general meeting statutory auditor participate audit committee meeting prepare write oral report audit service provide legally require result audits audit committee oversee assess auditor make recommendation auditrelated service include assurance board information authority accounting service provide auditor responsibility audit committee article necessarily provide statutory auditor bylaw statutory auditor participate service legal requirement meeting audit committee include attestation service comfort letter consent consultation report statutory auditor consolidated financial statement financial statement tax service include service respect find page respectively compliance tax return tax advice finance report service relate audit tax kpmg receive follow remuneration service include advice relate process service statutory auditor roche holding ltd improvement regulation training auditor roche company include chugai rochecomarticleofincorporation company formal policy governing limit agree audit committee engagement statutory auditor nonaudit potential nonaudit service engagement review service policy prohibit certain service policy authority proceed provide permit certain service give relationship independent proxy recent year bdo ag serve independent rule issue instruction proxy annual general meeting independent proxy rule electronic march shareholder elect bdo ag participation agm lay independent proxy period correspond invitation agm conclusion ordinary annual general regulate article incorporation meeting shareholder bdo ag pay service annual general meeting accord expenditure totalling chf chf information policy provide article incorporation relevant information document include corporate notice publish swiss official medium release investor update presentation gazette commerce daily newspaper analyst investor conference available designate board director basler zeitung internet publication available finanz und wirtschaft lagefi le temps neue rochecompublication order zrcher zeitung email baselwarehouseservicesrochecom fax roche report halfyear fullyear result business report publish print andor online contact address investor relation format medium event addition detail f hoffmannla roche ltd investor relation firstquarter month sale figure group finance basel switzerland publish year april october tel current list publication date available fax english german internet additional information include detail specific contact person available internet rochecomarticleofincorporation rochecommedia rochecominvestor rochecominvestorscontactscorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance addition roche establish business ethic officer network commit ensure incident report beir system enable roche group code conduct consistently chief compliance officer capture track comply roche group monitor allege violation initial report serve contact person shareholder employee local compliance officer resolution customer supplier general public issue relate implementation compliance business ethic incident record system code employee party group internal investigation department aware violation roche group code conduct regionallocal management receive specific bring attention manager concrete information allege violation supervisor local compliance officer report roche group code conduct certain chief compliance officer dr urs jaisli predefine category corporate governance direct phone number email sustainability committee audit ursjaislirochecom disclosure treat committee board director inform confidentially addition end substantial violation management corrective employee anonymously report irregularity action complaint mother tongue speakup line start december new compliance chief compliance officer report general tool group level socalle roche group code counsel submit regular report conduct help advice line introduce corporate governance sustainability committee strive provide guidance case question need audit committee board uncertaintie interpretation roche directors group code conduct reference document furthermore serve platform idea suggestion concern document nonapplicabilitynegative disclosure expressly note information contain provide swiss exchange corporate mention nonapplicable governance directive commentary thereto omission construe negative declaration rochecomcodeofconduct rochecomriskmanagementremuneration report roche material topic cover chapter executive remuneration remuneration report show commitment fair performancebase resultsoriente compensation policy link employee interest stakeholder group modern attractive condition key aspect roche interaction employee partners society general principle roche success depend substantially global company like roche marketcompetitive expertise motivation performance remuneration play key role performance employee conviction form basis base transparent compensation structure ensure compensation policy compensation package competitive structure individual component regularly roche aim remunerate employee fairly benchmarke swiss european international transparently line market condition criterion remuneration guideline enable participate appropriately underlie principle subject regular company success pursue goal provide outside comparison competitive performancebased resultsoriente compensation compensation policy factor safeguard roche future success key strive balanced mix fix variable element corporate culture offer employee compensation component gear employee condition good possible position management responsibility contribution share corporate goal improve healthcare patient include sound value compensation firstly variable component intend create system base integrity courage passion policy additional financial incentive achieve corporate time decentralise management rochecom goal innovation consistently high approach play major role wide scope reward level increase value company individual decisionmake respectful interaction create stakeholder group secondly order openness diversity wideranging training sound value allow employee manager participate development opportunity attractive working system company business success adequate compensation environment unidimensional diminishment rochecom measure key objective incentivise question remuneration fall far short livingour annual bonus payment longterm security value base programme roche commit fair performancebase resultsoriente compensation policy link employee interest stakeholder groupsremuneration report roche remuneration decision process approval framework overview term longterm orient performance year remuneration committee roche share plan psp award decide annually board director decide remuneration board board director act recommendation member member group corporate remuneration committee executive committee remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman c committee cec incl ceo roche group base payremuneration bonus c remuneration committee stocksettle stock appreciation right annual general performance share plan board director meeting recommendation remuneration committee decision pension c remuneration committee remuneration committee track market datum total aggregate amount base salary lead global pharmaceutical decision submit general company major swiss company report meet approval implement ordinance finding board external consulting excessive compensation list corporation firm pricewaterhousecooper pwc assist verordnung gegen bermssige vergtungen bei remuneration committee roche perform brsenkotierten aktiengesellschaften vegv market comparison advise information general meeting shall vote annually bind remuneration committee remit power effect approval remuneration procedure make remuneration decision board director resolve board find bylaw roche board director director corporate executive committee article incorporation detail outlined section principle govern specific remuneration component peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compare abb credit suisse lafargeholcim nestl sonova straumann swis ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation andr hoffmann chairman remuneration committee peer set abbott laboratories abbvie amgen astella astrazeneca abb bayer credit suisse roche bristolmyers squibb lafargeholcim eli lilly nestl glaxosmithkline sonova johnson johnson straumann merck co swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison company salary assessment pharma peer set major swiss companiesremuneration report roche procedure submit total board retrospective approval executive remuneration shareholder approval total aggregate bonus amount corporate annual general meeting executive committee chairman board year annual general meeting agm director financial year end shareholder approve total remuneration submit retrospectively ordinary agm board director corporate executive separate bind approval committee decide board director remuneration committee board director prospective approval respectively board executive aggregate remuneration submit prospectively agm separate accord approval agm roche bind approval period commit obtain separate ordinary agm bind shareholder approval total remuneration pay board director corporate executive committee follow approval total remuneration annual general meeting financial year financial year agm retrospective c chairman bod c bonus bonus financial year total cec corporate executive committee cec include bonus ceo roche group bonus financial year total prospective board director bod include c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec include ceo roche group cec base pay aggregate total remuneration agm agm ssar base pay rsus stocksettle stock appreciation right ssar indirect benefit restrict stock unit rsus indirect benefit peer set agm agm agm remuneration component overview remuneration element remuneration component link remuneration member board employee performance company financial director corporate executive committee performance commercial success compose follow element concrete align interest roche employee composition chart composition shareholder remuneration board director corporate executive committee lti remuneration component intend sustainably homogenously longterm fix base salary complement orient align management interest annual variable bonus shortterm incentive shareholder holder nonvoting equity sti perennial remuneration element security participate manager ssar psp longterm additional incentive achieve value growth incentive lti form longterm total shareholder return composition remuneration board director corporate executive committee annual remuneration element description c bod ceo roche group cec base pay monthly payment q uarterly remuneration payment bonus annual payment year year cash block nonvoting block non equity security voting equity andor share security andor share pension etc perennial remuneration element stocksettle stock appreciation right ssar performance share year plan psp block non vote equity security andor sharesremuneration report roche variable longterm sti base salary bonus indirect benefit employer contribution lti pension insurance contribution stocksettle stock roche roche connect appreciation right tax consulting service remuneration performance share plan expense allowance component children school cost foreign tax obligation ahvivalv fix base pay fix december end reporting year base pay cash payment determine january follow report year remuneration position base salary market datum lead committee decide bonus amount global pharmaceutical company footnote payable chairman board member major swiss company footnote corporate executive committee respect reflect individual ability experience current reporting year base performance performance time pay adjustment likewise aforementioned objective link individual performance account time remuneration committee decide prevail market condition company form bonus award ie cash payment overall financial situation andor nonvoting equity security andor share remuneration committee make review stocksettle stock appreciation right final decision individual base pay pay ssar longterm chairman board director member ssar entitle holder benefit financially corporate executive committee increase value roche nonvoting equity remuneration member board security grant date exercise date ssar grant vest bonus variable year bonus annually award individual exercise seven year grant date contribution value creation business year unexercised ssar lapse mean incentive strive outstanding compensation fair value result create new business opportunity ssar calculate grant date bonus amount link group divisional trinomial model american option core profit sale growth constant exchange rate detail operate profit capital charge opac base core operating profit core earning share ssar corporate executive committee nonvoting equity security ne growth constant allocate individually remuneration exchange rate product development pipeline committee discretion addition diversity employee manager environmental employee receive ssar new goal achievement measurable choice mix ssar rsus qualitative individual functional performance change vest expiration objective competitive reason roche period composition remuneration disclose individual performance objective component corporate executive committee member corporate executive committee enlarge corporate executive committee chairman starting performance share plan psp longterm grant vested recipient psp establish period year result nonvoting year base threeyear comparison equity security andor share remain block total shareholder return tsr peer year new choice mix company footnote ssar rsus change vest expiration period respective year psp consist composition remuneration component overlap performance cycle new cycle corporate executive committee enlarge start begin year cycle corporate executive committee finishing end year overlap performance cycle psp outlook psp psp psp start subject approval close december correspond change article incorporation annual general meeting plan key performance metric award composition remuneration component tsr calculate threemonth move longterm incentive lti corporate average rate start end executive committee enlarge corporate performance cycle payment psp executive committee change new psp award determine board director annual grant end basis act recommendation board director act recommendation remuneration committee remuneration committee determine payment ongoing psp psp psp award remuneration component end respectively reserve corporate executive lti corporate executive committee committee enlarge corporate executive enlarge corporate executive committee committee new award grant complement restrict stock unit rsus compose ssar rsus base exist individual longterm incentive corporate target value total lti corporate executive executive committee comprise psp committee member base pay award ssar approximately measure january year vest expiration period align ssar rsus restrict stock unit rsus longterm rsu award allocate individually rsus serve remuneration component corporate executive committee enlarge eligible roche employee rsus contain corporate executive committee remuneration right receive nonvoting equity security andor committees discretion unlike participant share threeyear vest period plus value programme member corporate adjustment equivalent executive committee enlarge corporate sum dividend pay vest period executive committee choice determine attributable number nonvoting equity mix rsus ssar security andor share individual award fouryear cliff vestingremuneration report roche new grant march vest schedule ssar currently threeyear remain participant ssar rsus annual vest align fouryear programme offer choice annual vest schedule new grant combination determine mix restrict stock unit rsus stocksettle stock appreciation innovative change roche long right ssar option instead ssar term incentive programme attractive enable country follow option offer roche attract motivate retain good talent align company longterm choice choice choice success ssar ssar ssar rsus rsus rsus indirect benefit show ceo roche group offer level choice empower participant chairman respectively member engage fully total reward enable corporate executive committee additionally well understand critical element receive indirect benefit payment pension compensation increases value programme fund mgb stiftung der f hoffmannla roche ag position roche peer group fr mitarbeitergewinnbeteiligung als ergn zung provide benefit expiration period der beruflichen vorsorge ie employee profitshare newly issue ssar extend currently foundation supplement occupational pension seven year year participant benefit insurance roche connect payment additional year exercise vest ssar foreign tax obligation tax consulting service vest schedule newly issue rsus annual expense allowance show change threeyear cliff vest fouryear individual member corporate annual vest year grant rsus executive committee receive payment vest available participant school cost child weight fixedvariable longterm remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable longterm ratio remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar psp relative value fix base pay sti variable lti longterm criterion bonus ssar psp individual target value minimum maximum performance criterion group objective group value development determine value development determine divisional business performance performance plus value performance plus value individual objective adjustment dividend adjustment dividend consider core profit sale ne grant nesshare grant growth constant exchange group performance tsr rate operate profit relation tsr performance capital charge opac base peer set tsr definition core operating profit core earning share nonvoting equity security ne growth constant exchange rate product development pipeline diversity employee manager environmental goal split group objective na b individual objective na na applicable assess consideration performance competitor macroeconomic development base annual base pay measure january year cycle detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration report roche remuneration board director resolution approval director table board remuneration chairman board activity roche pay legally require employer director member board director contribution total chf swiss social decide remuneration committee security programme provide retirement disability discretion take account market comparison unemployment benefit ahvivalv member board director legally remuneration form cash payment require contribution separately state annually track market datum director pay chairman board director lead global pharmaceutical company footnote major swiss company basic remuneration board director footnote assist consultancy exclude chairman remain unchanged pwc previous year board exception chairman board director separately submit total aggregate director bonus form block share bonus chairman board directors dr severin schwan executive member general meeting financial year board member board director retrospectively bind approval award share nonvoting equity security ssar maximum amount total aggregate remuneration board director period loan credit grant member ordinary general meeting board director ordinary general meeting table previous year general meeting capacity member chugai international prospectively bind approval council cic chugai pharmaceutical co ltd andr hoffmann receive honoraria remuneration member amount total usd chf board director member board director advisory service genentech scientific receive remuneration additional compensation review board prof dr richard p lifton receive form quarterly fix cash payment show honoraria amount total usd remuneration member board chf list member position committee membership chairmanship detidua remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration ch franz chairman total remuneration pay chairman board director hoffmann vicechairman j bell j brown p bulcke hauser rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff pr voser total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detiduaremuneration report roche total remuneration pay chairman form share block year payable board director march shareholder bind vote chairman dr christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director detidua remuneration member board director chf additional remuneration additional special total basic remuneration committee memberschair remuneration remuneration ch franz chairman total remuneration pay chairman board director hoffmann vicechairman j bell j brown p bulcke hauser march rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff pr voser p baschera retire march total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration pay period january march additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration include submission chairman total aggregate bonus employer contribution social bonus bind vote annual general security beneficial part totalling chf meeting chf exclude additional remuneration chairman board employer contribution pay ahvivalv director include bonus award chf totalling chf chf form sharesblocke year show form remuneration table section total remuneration pay chairman board director board remuneration pay member director submit remuneration committee board director bonus proposal adopt late chairman member board director dr franz b board dr christoph franz respect humer receive fee amount total financial year payable march exclude usd chf serve member legally require employer contribution ahviv chugai international council cic chugai alv shareholder bind vote pharmaceutical co ltd ordinary annual general meeting member board director william burns receive honoraria amount total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration pay detidua total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowance total form share block year calculation number share base price date transfer march april respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively nclude employer contribution social security beneficial part mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit additionally employer contribution ahvivalv chf chf pay form remuneration detiduaremuneration report roche retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base price date transfer march april april respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively submission board total aggregate dr severin schwans remuneration show future remuneration bind shareholder vote receive function ceo roche group board director propose member corporate executive committee ordinary agm approve board remuneration totalling include corporate chf exclude legally executive committee total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agm prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration comparison ordinary agm shareholder approve remuneration ordinary agm actual remuneration amount member board director chf exclude legally require employer ordinary agm approve board remuneration contribution ahvivalv exclude bonus total chf exclude legally require employer contribution ahviv alv exclude bonus period end ordinary agm prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding relate party note director andr hoffmann dr andreas oeri financial statement roche holding ltd member founder family closely significant shareholder addition associate belong contractually bind december december shareholder group pool voting right respectively member board director end group hold share person closely associate hold roche issue share detailed information share nonvoting equity security nes group find finance report note american depositary receipt adrs show roche group consolidated financial statement table security holding security holding share nes december december nonvoting nonvoting equity close relative equity close relative security security security security share ne holding share ne holding number number numbertype number number number numbertype number board director ch franz hoffmann j bell j brown p bulcke hauser nes nes rp lifton adr adr oeri b poussot schwan security holding security holding corporate executive committee corporate executive committee c suessmuth dyckerhoff pr voser total ne adr ne adrs share hold shareholder group pool voting right list jointly hold close relative roche adr american depositary receipt list otcqx wwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlying nesremuneration report roche remuneration corporate executive committee resolution approval member corporate executive remuneration member corporate committee receive remuneration work executive committee decide remuneration show remuneration committee discretion take account market ceo roche group dr severin schwan comparison explain detail previous year board payment base pay bonus ssar rsus indirect director separately submit total aggregate benefit employer contibution pension bonus corporate executive committee fund mgb roche connect expense allowance general meeting financial year etc dr michael heuer appoint retrospectively bind approval ceo roche diagnostic october include aggregate total remuneration maximum amount total aggregate corporate executive committee remuneration corporate executive committee period ordinary general meeting high total remuneration pay ordinary general meeting dr severin schwan member corporate table previous year general executive committee meeting prospectively bind approval dr severin schwan executive member board director receive remuneration primary remuneration member function ceo roche group reflect corporate executive committee high total remuneration pay member general provision assign authority decision corporate executive committee corporate executive committee remuneration include total pay corporate remuneration committee board executive committee total remuneration director outline remuneration pay member corporate executive decision process approval framework committee high total remuneration pay dr severin schwan member corporate executive committee chf base salary ssar pension fundsmgb insurance roche connect bonus subject approval total aggregate bonus corporate executive committee annual general meeting block share psp payment incl expense allowancefor tax consulting service total calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value include employer contribution social security beneficial part detailed calculation remuneration annual report number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit share block year calculation number share base share price date transfer march approval agm target number nonvoting equity security psp nonvoting equity security multiply nonvoting equity security price average month october december prior start performance cycle chf nonvoting equity security target number nonvoting equity security psp nonvoting equity security multiply nonvoting equity security price average month october december prior start performance cycle chf nonvoting equity security include annual expense allowance chf payment tax consulting service chf chf anniversary payment chf additionally employer contribution ahvivalv chf chf pay form remuneration base pay member corporate executive committee base pay chf r diggelmann retire corporate executive committee end september hippe g keller oday c wilbur total prorate remuneration period january september detidua detidua base pay dr michael heuer include aggregate total remuneration corporate executive committee remuneration report roche bonus member corporate executive committee total aggregate executive committee bonus bring forward remuneration committee board director bind vote annual general meeting determine corporate executive committee member bonuse base performance dr severin schwan member agree objective dr michael heuer corporate executive committee receive regular bonus chf bonus bonus cash payment interim function additional chf total march dr severin schwan receive bonus chf million propose include form roche share block year aggregate total remuneration corporate bonus payment march bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting r diggelmann retire corporate executive committee end september hippe g keller oday c wilbur total stocksettle stock appreciation right option trinomial model effective method ssar member corporate valuation american option consider executive committee possibility exercise option time prior ssar show ssar table maturity call american option compare entitle holder benefit financially european option allow exercise increase value roche nonvoting equity maturity date security ne grant date exercise date strike price ssar number ssar strike price expiry term multiyear plan closing price date grant value ssar show roche ne grant date ssar vest ssar table number year grant date vest ssar ssar calculate time issue exercise convert ne seven year enter value table page grant date unexercised ssar lapse ssar grant dr michael heuer subject compensation yearly vest show ssar table fair value include aggregate fair value ssar calculate grant total remuneration corporate executive date trinomial model american committee information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf strike price table ssar detidua stocksettle stock appreciation right ssar chf ssar ssar r diggelmann retire corporate executive committee end september hippe g keller oday c wilbur total grant ssar grant value chf ssar price chf expiry date performance share plan psp sum dividend pay vest member corporate executive committee period attributable number nonvoting psp consist overlap threeyear equity security share individual formance cycle new cycle beginning award grant require roche year cycle progress security perform well psp psp psp peer set event investment psp close december roche security underperform average return target share award deliver peer company few ne share award provision plan number nonvoting equity security nes share ne reserve plan reserve participant cycle member corporate executive committee number security actually award depend show table extent investment roche board director decide actual level security share ne outperform average ne share cash equivalent award psp return investment security issue set cycle close peer company comparison base financial year respectively aim security market price dividend yield ie psp provide incentive participant total shareholder return tsr reduce achieve longterm value growth roland effect shortterm market fluctuation security diggelmann daniel oday resignation price average month october potential award reduce december prior start performance cycle month october december dr michael heuer participate psp end cycle programme roche security perform well average end psp cycle base peer set board director elect threemonth average distribute dividend increase ne share award maximum totalling chf billion chf billion award double originallevel reserve target chf billion chf billion number ne share accord psp plus accord term plan participant value adjustment equivalent receive originally target share footnote detiduaremuneration report roche restrict stock unit member roche connect voluntary stock purchase plan corporate executive committee offer employee opportunity buy roche member corporate nonvoting equity security nes executive committee dr michael heuer receive equal annual salary discount rsus appointment ceo roche ne purchase plan subject diagnostic hold period year switzerland indirect benefit member addition member corporate executive corporate executive committee committee receive annual expense allowance employer contribution social security member payment foreign tax obligation scheme pension plan groupwide employee tax consulting service show table stock purchase plan roche connect respect member corporate executive committee show indirect benefit employer contribution table employer contribution show table detidua performance share plan psp fair value grant fair value grant nonvoting nonvoting equity security equity security ne ne price ne ne price average average month fair value month fair value target number october target number target number october target number nonvoting december nonvoting nonvoting december nonvoting equity security prior start equity security equity security prior start equity security ne performance ne ne performance ne psp cycle psp psp psp cycle psp psp number value chf value chf number value chf value chf r diggelmann hippe ga keller oday c wilbur total calculation value nonvoting equity security consideration reduction value block period year reduce market value calculation value nonvoting equity security consideration reduction value block period year reduce market value retire corporate executive committee end september detidua detidua indirect benefit employer contribution chf pension payment pension payment fund annual taxtax fund annual taxtax mgb expense roche consulting mgb expense roche consulting insurance allowance connect service insurance allowance connect service r diggelmann hippe g keller oday c wilbur total include employer contribution social security beneficial part r etire corporate executive committee end september mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit payment employer contibution indirect benefit remuneration member pension fund mgb roche connect expense corporate executive committee allowance etc dr michael heuer include pension totalling chf aggregate total remuneration corporate chf pay corporate executive committee executive committee member remuneration loan member total remuneration pay member corporate executive committee corporate executive committee base contractual obligation roche pay calendar year member individual member corporate executive corporate executive committee receive committee children school cost remuneration include bonus employer totalling chf chf contribution social security beneficial part payment dr michael heuer ceo aforementione additional payment include roche diagnostic totalling chf total remuneration member corporate chf exclude additional executive committee employer contribution pay ahvivalv totalling chf chf loan credit grant form remuneration member corporate executive committee additional remuneration maximum regular period notice member mention payment pay current corporate executive committee month member corporate executive committee changeofcontrol clause employment contract detidua detiduaremuneration report roche executive remuneration subject approval block year member annual general meeting corporate executive committee cash payment totalling chf respect submission executive total aggregate financial year chf bonus bind vote annual exclude legally require employer contribution general meeting ahvivalv submit propose total board director propose award member ordinary annual general meeting corporate executive committee bonus agm bind vote dr severin schwan form roche share retrospective approval member executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv submission executive total future aggregate incentive ssar calculate grant value remuneration bind shareholder vote consider reduction value block period board director propose applicable rsus calculate ordinary agm approve remuneration time reservation nonvoting equity security corporate executive committee totalling share consider reduction value chf exclude legally require block period contribution pension benefit employer contribution ahvivalv exclude legally require employer contribution exclude bonus period end ahvivalv contribution expense ordinary agm payment foreign tax obligation tax consulting service roche connect executive total future aggregate remuneration compose base pay longterm prospective approval member executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration exclude bonus period end shareholder prospectively approve ordinary agm remuneration member corporate executive committee comparison ordinary agm ordinary agm approve remuneration ordinary agm remuneration amount corporate executive committee totalling chf exclude legally require employer chf exclude legally require contribution ahvivalv exclude bonus employer contribution ahvivalv psp assumption maximum value prospectively approve total remuneration member executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm total remuneration calculate end calculation end corresponding agmagm period period agm agm actual total remuneration realise corresponding agmagm period base calculation end calculation end actual calculate restrospectively end end end correspond psp cycle psp cycle psp cycle approve limit calculation end period calculation end period yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus include assumption maximum possible award sharesnonvote equity security correspond psp cycle award share psp cycle originally include calculation maximum possible award total remuneration period agm agm reduce chf remuneration report roche clawback accord regulation psp programme addition applicable statutory provision originally target award ne share roche longterm incentive plan include option shall lapse compensation notice partially reclaim distribute compensation termination employment give reason result special circumstance clawback redundancy disability retirement employee voluntarily serve notice guideline security holding termination employment ssar board director decide ceo rsus unvested date roche group cec member acquire termination employment lapse immediately share andor ne equivalent annual base compensation salary ceo roche group equivalent annual base salarie annual base salary termination employment result respectively end retain misconduct ssar rsus grant holding long serve cec outstanding vest unvested shall lapse exception cristina wilbur join immediately compensation accord corporate executive committee ssar plan rule misconduct fulfil requirement end participant include inter alia members corporate executive committee activity lead disciplinary action fulfil requirement repeat willful failure perform duty reasonably assign roche security holding violation law public regulation december december commission crime respectively member cec person gross negligence willful misconduct employment closely associate hold security show engage conduct bring disgrace disrepute table share nonvoting equity security roche andor subsidiary nesand ssar violation roche directive guideline relate business conduct type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary share nonvoting equity security nes december december close relative close relative share ne security holding share ne security holding number number numbertype number number numbertype corporate executive committee share ne share schwan hippe ga keller oday c wilbur heuer na na na total na applicable exclude rsus ssar number ssar hold december corporate executive committee schwan hippe g keller oday wilbur heuer total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option v alue accord correspond annual report e xcluding closerelative ssar price chf expiry date grant value ssar chf holding totalstatutory auditor report roche general meeting roche holding ltd basel audit accompany remuneration audit involve perform procedure obtain report roche holding ltd year end audit evidence disclosure december audit limited remuneration report regard compensation information accord article ordinance loan credit accordance article excessive compensation stock exchange ordinance procedure select depend list company ordinance contain auditor judgement include assessment section mark audit grey line include risk material misstatement remuneration respective footnote page report fraud error audit remuneration report include evaluate reasonableness method apply value component remuneration assess overall presentation responsibility board director remuneration report board director responsible preparation overall fair presentation believe audit evidence obtain remuneration report accordance swiss law sufficient appropriate provide basis ordinance board director opinion responsible designing remuneration system define individual remuneration package opinion opinion remuneration report year auditor responsibility end december roche holding ltd responsibility express opinion complie swiss law article accompany remuneration report conduct ordinance audit accordance swiss auditing standard standard require comply ethical requirement plan perform audit obtain reasonable assurance remuneration report comply swiss law article ordinance kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve independent assurance report roche sustainability report corporate governance sustainability committee chemical industry council cefic gri standard roche holding ag basel publish october global reporting initiative gri roche group internal corporate reporting manual engage perform assurance procedure provide sustainability report guidanceeconomic performance limited assurance aspect sustainability issue june report roche hold ag basel consolidate roche materiality determination process corporate level subsidiary roche include annual report report base gri standard publish october global reporting initiative gri scope subject matter define guideline people contribution limited assurance engagement focus follow datum key figure sustainability risk opportunitie information disclose sustainability report roche internally gather collate aggregated year end december management reporting process respect inherent limitation sustainability report material aspect accuracy completeness sustainability indicator preparation safety security health environmental subject inherent limitation give nature method protection contribution people key figure determine calculate estimate datum assurance relate control environment relation datum report read connection roche internal aggregation key figure guideline definition procedure report materiality determination process roche group level sustainability performance according requirement gri standard disclose report roche responsibility design sustainability risk opportunitie roche corporate governance sustainability committee determination process base roche corporatelevel activity responsible subject matter criterion disclose paragraph risk management selection preparation presentation select report information accordance criterion responsibility people key figure disclose page report include design implementation maintenance relate key figure include greenhouse gas emission scope internal control relevant reporting process free scope result business travel compress air material misstatement fraud error liquid nitrogen waste table graphs page report responsibility figure roche group level relation contribution responsibility form independent opinion base donation disclose report limited assurance procedure come attention indicate identify sustainability information carry work datum report prior select contain report state material reporting period perform work respect respect accordance report criterion projection target plan perform procedure accordance criterion international standard assurance engagement isae management reporting process respect revise assurance engagement audits review sustainability report key figure prepare roche historical financial information respect greenhouse base internal policy procedure set forth gas emission international standard assurance follow engagement isae assurance engagement greenhouse roche group internal sustainability report guideline gas statement issue international auditing assurance base responsible care health safety environmental standard board standard require plan perform protection reporting guideline publish european assurance engagement obtain limited assurance theindependent assurance report roche identify sustainability information prepare material review relevant documentation sample basis include aspect accordance roche internal policy procedure roche group sustainability policy management report structure documentation limited assurance engagement isae revise reviewing principle roche materiality process isae substantially scope reasonable assurance provide definition development adherence engagement relation risk assessment procedure gris environmental social economic reporting requirement include understand internal control procedure address soundness identification process perform response assess risk consequently determination impact stakeholder peer competition nature timing extent procedure gather sufficient review integration relevant regulatory requirement integration appropriate evidence deliberately limited relative reasonable key organisational value objective report prioritisation assurance engagement assurance obtain material aspect limited assurance engagement reasonable inspect integration sustainability risk assurance engagement procedure select depend opportunity group risk management process assurance practitioner judgement adherence internal guideline assessment process datum consolidation independence quality control review management sustainability reporting comply independence ethical process contribution people key figure requirement code ethic professional accountant assess consolidation process datum roche group level issue international ethic standard board accountant found fundamental principle integrity objectivity conduct work datum outline professional competence care confidentiality subject matter define believe evidence professional behaviour obtain sufficient appropriate provide basis assurance conclusion firm apply international standard quality control accordingly maintain comprehensive system quality control conclusion include document policy procedure compliance base work perform describe report ethical requirement professional standard applicable identify roche sustainability report come legal regulatory requirement attention cause believe material respect roche group internal sustainability report guideline summary work perform base gri standard cefic guideline assurance procedure include follow apply work roche materiality determination process corporate level review application roche group guideline disclose adhere principle guide factor review application roche group internal corporate eg soundness stakeholder determination peer review relevance sustainability contribution guideline regulatory environment integration key organisational value site visit management inquiry objective define gri standard visit select site roche pharmaceutical diagnostic design sustainability risk opportunitie division usa germany greece colombia italy determination process corporate level disclose selection base quantitative qualitative criterion function design interview personnel responsible internal sustainability internal reporting process collect aggregate reporting datum collection site visit people contribution datum function design roche group level determine understand application provide appropriate basis disclosure roche internal sustainability guideline sustainability information mention subject matter assessment key figure disclose sustainability report roche annual perform test sample basis evidence support select report state accordance report criterion contribution people key figure eg roche accident rate energy consumption greenhouse gas emission relate energy consumption water waste contribution public policy pricewaterhousecooper ag stakeholder representation woman key leadership role concern completeness accuracy adequacy consistency christophe bourgoin fabienne fricker review documentation analysis relevant policy principle zurich january modern technology digitalisation sophisticated datum analysis support scientist roche research product development picture show scientist prepare sample analysis key date publish f hoffmannla roche ltd annual general meeting group communications march basel switzerland tel firstquarter sale wwwrochecom april orderdownload publication halfyear result internet rochecompublication july email baselwarehouseservicesrochecom fax month sale october medium relation tel email mediarelationsrochecom investor relation tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement forwardlooke statement earning share growth statement profit forecast interpret annual report contain certain forwardlooke mean roche earning earning share statement forwardlooke statement subsequent period necessarily identify word believe expect match exceed historical publish earning anticipate project intends seek earning share roche estimate future similar expression discussion thing strategy goal trademark legally protect plan intention factor cause actual result differ materially future link thirdparty page provide convenience reflect forwardlooke statement contain express opinion content annual report price thirdparty page expressly disclaim product initiative competitor legislative liability thirdparty information use regulatory development economic condition delay inability obtain regulatory approval bring product market fluctuation roche annual report publish german currency exchange rate general financial market english condition uncertaintie discovery development marketing new product new reporting consist actual annual report use exist product include limitation finance report contain annual negative result clinical trial research project financial statement consolidate financial unexpected effect pipeline market statement regard content management product increase government pricing pressure report article incorporation consist interruption production loss inability aforementione report exception obtain adequate protection intellectual property remuneration report right litigation loss key executive employee adverse publicity print nonchlorine bleach fsccertified paper news coveragewe share purposedoe patient need nextwe believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world roche content believe urgent deliver medical overview solution right noweven develop chu ar rt mra ne g sy shareholder letter innovation future passionate ceo shareholder letter transform patient live business performance group performance courageous decision action phia ag rmno ct eic ip ce ar lsfo pr em rfa rc ance believe good business mean science innovation well world dd ee vn et li ofy pi ng g die ad gi nc oa sl tn ice e ted sts health app come work day access healthcare join force difference commit scientific rigour enable sustainable healthcare funding unassailable ethic access medical people aannnnuuaall rreeppoorrtt learn leadership development innovation today worldclass talent shape future build well tomorrow environment reduce energy water consumption proud reduce emission air water work c pt ar reo tn nm g et rh inem gn tn ou g n lo aci kat el ac dme iffmn erug en na ct eig ese ment function company world enn sut ing gr bi ut siy ne si sn co nb tiu nus iti yness develop last partnership corporate governance roche b co oa rr pd ro af e eir xe ec cto ur tis committee remuneration report principle remuneration component e roche annual report f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom journey recovery woman show cover roche annual report year appear cover report year f hoffmannla roche ltd basel switzerland midst receive treatment breast cancer trademark legally protect wwwrochecom photographed come powerfully cover year later enjoy life p e n innovation p r n e r introduce ocrevus medicine people autism collaboration partner treatment form multiple spectrum disorder phase iii authority develop sclerosis ocrevus demonstrate study common nextgeneration diagnostic test superior efficacy reduce neurodevelopmental condition medicine aim relapse slow worsen characterise difficulty diagnose treat multi disability cause ms social interaction drugresistant bacterial infection cover show woman diagnose cancer